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Abstract
Fundamental differences in the B cell locus, V(D)J repertoire, and Marburgvirus
epitope recognition of the Egyptian rousette bat that may allow for asymptomatic
presentation
Maggie L. Bartlett, Ph.D.
University of Nebraska, 2020
Supervisor: Mariano Sanchez-Lockhart, PhD.
Marburg virus (MARV) causes a hemorrhagic fever in humans but is asymptomatic
in a known reservoir, the Egyptian rousette bat (Rousettus aegyptiacus, ERB).
Understanding the mechanisms that drive these different outcomes could potentially
advance the development of therapeutics. The immunoglobulin (Ig) response to MARV
infection in ERBs in known to serve a role in protection. The Ig germline encodes Variable
(VH), Diversity (DH), and Joining (JH) genes that then recombine (V(D)J) to make up the
binding site of an Ig. Understanding the gene composition of the Ig germline is critical to
defining the potential B cell repertoire. We hypothesize that the B cell repertoire
contributes to the ability of ERBs to overcome MARV infection. However, to study V(D)J
rearrangement in ERBs, an accurate annotation of the Ig loci is needed. We constructed
one contiguous locus which allowed us to unequivocally define genes and expansions.
We described all VH, DH, and JH genes which were only partially annotated or missing
entirely in the previous assembly and found an expansion of IGHV genes associated with
protection from various pathogens in humans. Strikingly, we found the presence of two
functional IgE genes, something not found in any other mammal to date. This is the first
complete IGH locus for a bat species and one of only a handful for mammalian species.
We conducted in silico functional prediction assays for the Ig isotypes and subclasses to
evaluate their theoretical functions and examined components of innate immunity that can
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interact with Igs. We characterized the B cell receptor (BCR) repertoire of ERBs and
defined their B cell diversity mechanism to be somatic hypermutation, which is elevated
relative to humans. Finally, we assessed the epitope recognition profile of ERBs to MARV
and identified a novel region of recognition that may prevent viral escape which could
ultimately protect ERBs from MARV. These unique features of ERB immunoglobulins may
contribute to the asymptomatic presentation of MARV and substantially advance the field.
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Chapter 1:

Introduction

Zoonotic Diseases
Zoonoses are aliments that are transmitted from animals to humans or vice versa
[1]. Zoonotic diseases have a significant effect on public health and studies show that
approximately 75% of all emerging infectious diseases in humans originate from animals
[1]. These include oubreaks caused by filoviruses, lyssaviruses, alphaviruses,
arenaviruses, influenza viruses, flaviviruses, coronaviruses, Salmonella spp., Brucella
spp., Leptospira spp., Trypanosoma spp., Borrelia spp., Rickettsia spp., Mycobacterium
spp. and many more [2]. These can be transmitted by consumption of contaminated food
and water or direct or indirect contact with infected animals, insects, or humans. As
zoonoses constitute 58-61% of all communicable diseases worldwide understanding hostpathogen interaction in reservoir hosts is paramount to identifying novel mechanisms of
control [3]. As we increase our encroachment on habitats of previously undisturbed
species, we also increase our risk to potential spillover events. The incidence and
prevalence of zoonotic diseases have been on the rise since the 1940s, likely due to
increased travel, urbanization, demographic changes, land encroachment, agricultural
practices, and lifestyle changes [4]. Studies across the 27 terrestrial mammalian orders
for zoonotic potential suggested that zoonoses were correlated to species richness in an
order [4]. While zoonotic diseases are found in 21/27 mammalian orders to date, the most
species-rich orders have the greatest number of unique pathogens. Rodentia is the most
abundant and species-rich among mammals of which 244/2220 species (10.7%) carry 85
known unique zoonotic diseases [5]. The second most diverse order is Chiroptera (bats)
and accounts for ~20% of classified mammals [6]. This order includes 108/1100 (9.8%)
zoonotic hosts with a total of 27 unique zoonoses described thus far [5].
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Bats as viral reservoirs
Within both Chiropteran suborders, Yinpterochiroptera and Yangochiroptera, it is
well established bats host more zoonotic viruses per species than other studied mammals
with some bats identified as the natural reservoirs of zoonotic pathogens [7-9]. Bats are
uniquely positioned to readily spread diseases, as they are the only mammals capable of
flight, are highly social, and long-lived [8]. These features mean bats cross continental
boundaries more easily than other terrestrial mammals. Further, it is known that bats often
co-habitat with other bat species and migrate to and from distant caves, bringing the
viruses they harbor with them [10]. Bats also aggregate in groups and pass pathogens
back and forth through play biting and exchange of bodily fluids, an ideal environment for
a pathogen to spread for which co-housing experiments have confirmed [11]. In addition,
bats can live decades compared to rodents who live years. Bat longevity paired with the
seasonal dynamics of viral infections within colonies maintains viruses in nature as colony
seropositivity is linked to biannual birthing circles [10, 12-14]. As zoonoses account for
more than half of all emerging infectious diseases, understanding host-pathogen
interactions is paramount to preventing zoonotic events where viruses jump from animals
to other animals or to humans. Thus, it is crucial to world health efforts to understand hostpathogen interactions within reservoir hosts and specifically, identify how bats successfully
withstand viral infections that are pathogenic in humans.
Distinct viruses associated with specific bats
There is growing evidence to support bats as viral reservoirs, and specific bat
species are associated with distinct viruses. Flying foxes, of the Yinpterochiroptera
suborder, include 60 known species and are considered the reservoirs for the
paramyxoviruses, Nipah virus (NiV) and Hendra virus (HeV) [15, 16]. . Paramyxoviruses
are negative-stranded RNA viruses with two surface glycoproteins, an attachment protein,

3
and a fusion protein. More than 100 paramyxoviruses have been identified in bats and
rodents worldwide [17-19]. The Paramyxoviridae family includes some of the most
significant livestock and human viruses such as mumps-, measles-, distemper-,
parainfluenza-, Newcastle disease-, respiratory syncytial virus and metapneumoviruses
[20]. A novel paramyxovirus, Sosuga virus (SOSV), was isolated from ERBs after an
incidental human case, highlighting the potential for other viral spillovers beyond what is
currently known [21].
Chinese horseshoe bats, of the Yangochiroptera suborder, are the reservoir for
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) [22]. The Coronavirus
(CoV) responsible for the outbreak that started in Wuhan, China in 2019 is also believed
to have originated from a bat strain. The novel CoV, named SARS-CoV2, is the causative
agent of Coronavirus Disease 2019 (COVID19) and has spread worldwide affecting
several countries including the US [23]. Even though an intermediate host is suspected
(currently thought to be the pangolin), the most likely origin based on sequence homology
is a bat- underscoring the importance of understanding host-pathogen interactions
particularly in bats [24]. To date numerous CoV have emerged that cause severe disease
including: (SARS), Middle East respiratory syndrome (MERS), porcine epidemic diarrhea
(PED) and severe acute diarrhea syndrome (SADS). Similar to filoviruses and
paramyxoviruses, there is no evidence that CoVs cause disease in bats studied [25].
Although there is mounting evidence of distinct viruses associated with only
particular species of bats, increased surveillance suggests these pathogens may be more
widespread in different bat species than previously anticipated [26]. This is supported by
the numerous novel viruses that have been collected from various bat species including
members of the viral families: Astroviridae, Bunyavirdae, Circoviruidae, Parvoviridae,
Partitviridae,

Coronaviridae,

Picobirnavirdae,

Adenoviridae,

Herpesviridae,
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Papillomaviridae, Phenuiviridae, Picornaviridae, Orthomyxovirdae, and Filovirdae [27]. To
this end, what is found for one bat species and virus may not be applicable to all bats and
all viruses as there are clear associations and host-pathogen interactions that have yet to
be explained.
However, a majority of studies on bat antiviral immunity have been conducted on
only two species, ERBs and the closely related Pteropus alecto. While both are reservoirs
to RNA viruses (MARV, RAVV, SOSV and HeV, Broorne viruses, respectively), the viruses
as well as the mechanisms to control infection appear to have been achieved through
distinct pathways [8]. Most notably through the difference in IFN induction post infection
which appears to not only be upregulated post HeV and NiV infection, but constitutively
expressed in P.alecto [28]. Post MARV infection in ERB cells, very few IFN genes were
induced, although mild upregulation of putative unannotated antiviral paralogs were
detected, as well as elevated basal expression of key antiviral genes in uninfected cells
[29]. These data support better characterization of bat immunity and call attention to the
importance of not attributing a finding in one bat to all bats.
The Egyptian rousette bat as a viral reservoir
The Egyptian rousette bat (ERB, Rousettus aegyptiacus), a member of the
Yinpterochiroptera suborder, is a known reservoir for the filoviruses Marburg virus
(MARV), Ravn virus (RAVV) and the paramyxovirus, SOSV [21, 30]. Interestingly, ERBs
display no disease manifestation upon infection with MARV, RAVV or SOSV. However,
humans and non-human primates (NHPs) present with a severe hemorrhagic fever and
lethality up to 90% to MARV and RAVV [31], and severe disease to SOSV [21].
Understanding how this reservoir host controls these viruses could advance therapeutics
for these viruses for which no FDA treatments currently exist. As SOSV was recently
identified and only has one known human case, my work focused on filoviruses and ERBs.
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Filoviruses
Filoviruses are non-segmented, negative-strand, RNA viruses from the family of
Filovirdae which includes Ebolaviruses, Marburgviruses, and Cuevaviruses. Ebolaviruses
(Zaire virus, Sudan virus, Bundibugyo virus, Taï forest virus, Bombali virus, and Reston
virus) differ by 2.7-5.2% at a nucleotide level while Marburgviruses (Ravn virus (RAVV)
and Marburg virus (MARV)) differ by 20% at a nucleotide level [32]. Further, some species
are represented by a single lineage, and new genuses are being identified with some
frequency [33-36]. As increased surveillance and genome sequencing occurs, more are
likely to be discovered like the recent discovery of the Dianiovirus family member, Měnglà
virus (MLAV) [37]. To date, only four Ebolaviruses (Zaire virus, Sudan virus, Bundibugyo
virus, Taï forest virus) and the two Marburgviruses are known to cause disease in humans.
Reston ebolavirus is known to cause disease in NHPs and pigs, but not in humans. The
field recently proposed a new taxonomy to integrate the novel filoviruses recently
discovered that have no known human cases (Table 1) [33].
With an average genome of 19kb, all filoviruses to date have encoded seven
proteins: nucleoprotein (NP), glycoprotein (GP), RNA-dependent RNA polymerase (L),
viral proteins (VP) 24, 30, 35, and 40 (VP24, VP30, VP35, and VP40) [38]. MARV was the
first filovirus discovered after laboratory workers in Marburg, Germany were exposed to
the virus after contact with infected cells from African green monkeys (Chlorocebus
aethiops) [39]. Small outbreaks of MARV and RAVV occurred between 1975-1997 with
links to bat caves [39], and the second largest scale outbreak is thought to have originated
from a gold mining cave [40]. The following three outbreaks and two single human cases
in Uganda were associated with Kitaka and Python cave, respectively [40]. To confirm
these associations, samples were taken from bats in both caves and not only were both
populations seropositive for virus, fully infectious virus was isolated [30]. Infectious MARV
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has now been isolated from 21 bats which represent the only successful filovirus isolations
from any bat species to date [30, 41]. Follow-up experimental inoculation studies
confirmed the susceptibility of ERBs to MARV/RAVV including viremia, widespread
dissemination in tissues, viral shedding in urine, feces, and saliva [42, 43]. In addition, batto-bat transmission has been shown experimentally as well as long-term immunity to
reinfection after challenge [11].
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Table 1 : Taxonomy of the viral family Filovirdae and associated bat species
Genus

Species

Virus

Abbreviation

Bat associated

Cuevavirus

Lloviu cuevavirus

Lloviu virus

LLOV

Miniopterus schreibersii2

Dianloviurs

Mengla dianlovirus

Měnglà virus

MLAV

Ebolavirus

Bombali ebolavirus

Bombali virus

BOMV

Bundibugyo ebolavirus

Bundibugyo virus

BDBV

Reston ebolavirus

Reston virus

RESTV

Sudan ebolavirus

Sudan virus

SUDV

Tai Forest ebolavirus

Taï Forest virus

TAFV

Zaire ebolavirus

Ebola virus

EBOV

Marburg marburgvirus

Marburg virus

MARV

Ravn virus

RAVV

Marburgvirus

Striavirus

Xilang striavirus

Xīlǎng virus

XILV

Thamnovirus

Huangjiao thamnovirus

Huángjiāo virus

HUJV

Cynopterus sphinx,
Hipposideros pomona,
Miniopterus schreibersii,
Myotis pilosus,
Pipistrellus, Rousettus
amplexicaudatus,
Rousettus leschenaultii

Eidolon helvum,
Epomops franqueti2,
Epomophorus
gambianus, Hypsignathus
monstrosus2,
Micropteropus pusillus,
Myonycteris torquata2,
Rousettus aegyptiacus,
Rousettus leschenaultii
Rousettus aegyptiacus1,
Epomops franqueti,
Hypsignathus
monstrosus, Miniopterus
inflatus2, Rhinolophus
eloquens2
Rousettus aegyptiacus1

Colored viruses associated with human diseases. All bats were positive by antibody titer,
reservoir species indicated1 and bats with additional PCR confirmation2. [33-35, 37].
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Marburgvirus and significance
The Ebola virus disease (EVD) outbreak in Western Africa (2013-2016) that
caused more than 11,323 deaths accelerated the urgency and emphasized the significant
need for effective filovirus treatments [44]. In fact, one EVD outbreak in the Democratic
Republic of the Congo (DRC) is ongoing and as of January 29th of 2020 had 66% fatalities
and 3,304 confirmed cases [45, 46]. While Marburg virus disease (MVD) outbreaks have
not reached the same proportions of the EVD outbreaks, the 1998-2000 DRC MVD
outbreak had a case-fatality rate of 83% (128 deaths), and the 2004-2005 Angola of 90%
(227 deaths), underscoring the potential risk MARV poses to public health [39] (Table 2).
Further, a strain similar to Angola MARV was recently identified as circulating in ERBs in
Sierra Leone posing the potential for new spillover events [47]. Although vaccines,
monoclonal antibodies (mAbs), and antiviral drugs are under development for filoviruses
[48-54], there are no FDA approved medical countermeasures (MCMs) for MARV.
However, similar to EBOV many different approaches are being pursued, although the
work is significantly behind for MARV. Both preventative and post-exposure treatments
have been explored for MARV including lipid nanoparticle delivery of anti-MARV NPtargeting small interfering RNA (siRNA), vaccination with recombinant vesicular stomatitis
virus-GP, mAbs, phosphorodiamidate morpholino oligomers and broad-spectrum
nucleoside anologs [55-58]. However, these are only shown to be effective in NHPs if
treatment is initiated within 48-72 hours of exposure and have not been tested against
more than one strain of MARV in most cases. As early diagnostics are still limited for
MARV this timeline is not feasible in an outbreak scenario [59]. This emphasizes the
significant need for early detection as well as novel approaches to treatment to minimize
and control future outbreaks.
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Table 2 : Outbreaks of MVD since identification
Year(s)
Country
1967
Germany/Yugoslavia
1975
South Africa
1980
Kenya
1987
Kenya
1990
Russia
1998-2000
DRC
2004-2005
Angola
2007
Uganda
2008
USA*
2008
Netherlands*
2012
Uganda
2014
Uganda
2017
Uganda
* Case exported from Uganda

Cases
31
3
2
1
1
154
252
4
1
1
15
1
3

Deaths (%)
7 (23%)
1 (33%)
1 (50%)
1 (100%)
1 (100%)
128 (83%)
227 (90%)
1 (25%)
0 (0)
1 (100%)
4 (27%)
1 (100%)
3 (100%)

Outbreaks of MVD. Adapted from CDC report retrieved from:
https://www.cdc.gov/vhf/marburg/resources/outbreak-table.html, [60-63].
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Marburg virus pathogenesis and immune responses in humans
In humans, initial exposure to MARV is thought to occur through a mucosal route
from contact with infected bodily fluids. Virions infect macrophages, monocytes, and
dendritic cells via micropinocytosis and are transported to secondary lymph tissues.
MARV replication in macrophages and monocytes has been shown to occur as early as
24-48 hours in guinea pigs and cynomolgus macaques, respectively [39]. The virally
infected cells travel to secondary sites including the lymph nodes, spleen and liver where
most severe necrotic lesions occur [39]. Although lymphocytes have been shown to not
be susceptible to MARV infection, massive bystander apoptosis of lymphocytes is a MVD
hallmark and impedes the patient’s ability to overcome disease [64-66]. The mechanisms
for this are not fully delineated but it is though that cytokine secretion from MARV-infected
cells are a major factor including TNFα [67], supported by improved survival in guinea pigs
treated with anti- TNFα antibodies [68]. While MARV-infected human sera is not readily
available to assess, levels of cytokines and chemokines following infection in NHPs,
guinea pigs, and mice have been well documented [64, 69-71]. In late infection stages
MARV particles from nearly every organ of NHPs can be isolated, however despite this
widespread viral dissemination only minor inflammation is observed in infected tissues
and organs [64, 66, 72]. Unfortunately, these data are not consistent between models so
drawing correlates to what might be seen in humans remains unclear [39]. Instead I will
focus on the findings from human outbreaks and human primary culture in response to
MARV. Clinical symptoms appear in three phases. The first phase of symptoms (malaise,
headache, fever) appear three to nine days post exposure and are not indicative of a
particular disease [73]. Symptoms worsen during the second phase of infection including
diarrhea, nausea, vomiting, high fever, and a maculopapular rash presents typically within
a week. Liver enzymes are increased during this period and lymphopenia and
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thrombocytopenia are typically observed. The third phase of infection consists of severe
hemorrhage and organ failure or convalescence. At autopsy, large necrotic areas were
present in almost every organ except the lungs, skeletal muscles and skeleton with very
large necrotic areas in the testicles and ovaries [39, 74]. Human monocytes and
macrophages produce pro-inflammatory cytokines interleukin-1β (IL-1β), IL6, IL8 after
infection which are thought to subsequently lead to vascular permeability and coagulation
abnormalities [67, 75]. Moreover, MARV proteins VP24 and VP35 inhibit type I interferon
(IFN) which allows for uncontrolled viral replication [76]. Hemorrhage and death appear to
occur as a complication of the immune response rather than the virus infection itself [62,
77]. Patients who do not succumb are shown to generate a CD4+ T cell response with
limited CD8+ T cells [78]. The humoral response has a role in protection which is best
demonstrated by the presence of protective antibodies that can be transferred to naïve or
sick individuals (humans or NHPs) resulting in prevention of diseases or better survival
rates [79-82]. These findings support the notion that the humoral response is an effective
MARV defense. However, it is well known that antibody titers alone do not correlate with
survival outcome [83]. This observation suggests that antibody function, not just quantity,
is a critical correlate of protection.
Marburg virus pathogenesis and immune responses in ERBs

For ERBs, it is thought infection occurs through either the mucosal route or through
play-biting [11, 84]. It is proposed ERBs control MARV through a differentially regulated
innate response that lacks the inflammation seen in humans, coupled with a protective
adaptive response that resolves infection [85]. ERBs do not upregulate IFN or IFN
stimulated genes (ISGs) post MARV infection in vitro [29] or in vivo (manuscript submitted,
Nature Communications) despite an expansion of these genes. These findings emphasize
the importance of combining transcriptomic, genomic, and functional studies as some
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expansions in the genome that were thought to likely be induced by infection were shown
to later be irrelevant to MARV infection such as the expansion of IFN genes [29, 85].
A recent study sought to define the clinical and histopathologic effects in bats post
MARV challenge as little was known compared to humans. No animals became febrile or
lost weight while white blood cell counts increased in infected ERBs [86]. A blood
chemistry panel revealed mock and infected individuals only differed in the liver enzyme
alanine aminotransferase (ALT), however, the increase was mild compared to the
elevated amounts seen in humans post infection. No significant gross lesions were found,
although some subjects had liver lesions between days 6-8 post infection which resolved
and coincided with the ability to detect MARV antigen in blood and tissues examined [86].
Not only are ERBs known to produce antibodies to MARV, but maternal antibodies
provide passive immunity to juvenile bats [87]. Further, infected ERBs shed virus for three
weeks post infection and can transmit the virus for up to four months after initial infection
[87]. Viral maintenance in ERB colonies is suspected to occur through a decrease in
antibody levels over time which leads to an increase in viral load from residual virus,
resulting in shedding and subsequent infection of other ERBs [11, 87, 88]. The importance
of the Ig response in control of MARV infection in ERBs is underscored by the decrease
in viremia that corresponds with an increase in antibody titer (Figure 1) [11]. Despite
knowing Igs appear to be important post MARV challenge for subsequent exposures,
nothing is known about how ERBs form their B cell receptor (BCR) repertoire and what
that repertoire recognizes.
To better understand the humoral responses in ERBs, we sought to define their
germline Ig genes as well as associated molecules like FcR, complement, and pentraxins.
Previous work had highlighted the significant differences at a genome level between other
facets of the immune response in ERBs [85]. Further, these data drew attention to the
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potential of ERBs to rapidly create protective antibodies, or have a population of natural
IgM capable of viral control while humans require appropriate supportive care to survive
long enough to produce protective antibodies. Thus we also sought to define the BCR
repertoire and antigen recognition of ERBs.
Antiviral immune response overview
Innate
The immune system is comprised of innate and adaptive immunity [89]. The innate
immune system recognizes viral infections through pattern-recognition receptors (PRRs)
capable of detecting genomic DNA, single stranded or double stranded RNA, and RNA
with a 5'-triphospate [90]. Three classes have been shown to be associated with virusspecific recognition: Toll-like receptors (TLRs), retinoic acid-inducible gene I (RIG-I)-like
receptors (RLRs), and NOD-like receptors (NLRs) [91]. These receptors are present in
various cell types from both the innate and the adaptive arms of the immune system,
including epithelial cells, NK cells, myeloid lineage cells, DCs, B cells, and T cells [91].
Activation of these receptors leads to induction of type I IFNs that trigger the Janus
kinase/signal transducers and activators of transcription (JAK/STAT) signaling cascade
which upregulates hundreds of genes to ultimately render cells resistant to infection or
better able to block viral replication [92, 93]. In human cells infected with MARV, VP35
inhibits IFN production at numerous steps of the signaling pathway downstream of RLRs
[94]. In addition to suppression of type I IFNs, VP35 inhibits the IFN-induced protein kinase
R (PKR) pathway in humans, but not in ERB cells [95].
Another mediator of the innate antiviral response are pentraxins, which can
stimulate the complement pathway resulting in virus neutralization [96, 97].

The

complement system is a significant component of innate immunity and is comprised of
soluble factors and cell surface receptors that sense and respond to invading pathogens
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[98]. The complement system is thought to link innate and adaptive responses by a myriad
of mechanisms including enhancement of humoral immunity, regulation of Ig effector
mechanisms, and modulation of T cell function [99]. There are three activation pathways
(classical, alternative, and lectin) that converge on complement component 3 (C3).
Numerous viruses have evolved mechanisms to evade complement, supporting its
protective qualities. Viruses can be directly inactivated by complement after being bound
by mannose binding lectin (MBL), which has been shown effective in HIV, EBOV, MARV,
and SARS-CoV [100].
Adaptive
During this primary innate immune response, antigen presenting cells (APCs) such
as DCs and macrophages recognize pathogens with PRRs and present antigen to T cells
to produce cytokines which promote B cell maturation and antibody production. These B
cells then can undergo somatic hypermutation (SHM) and clonal selection to become longlived plasma cells to produce antigen-specific immunoglobulins (Igs) in the secondary
immune response. Igs are heterodimeric proteins comprised of two heavy (IGH) and two
light (IGL) chains. They have a fragment antigen-binding (Fab) region and fragment
crystallizable (Fc) region that confers effector function [101]. The Fab domain is further
composed of a Variable (VH) gene, Diversity (DH) gene, and Joining (JH) gene from the
heavy chain and a Variable (VL) gene and Joining (JL) gene from the light chain. The
breadth and specificity of the B cell response is defined initially by the germline
composition of these genes. Further mechanisms of diversity occur, including SHM,
through affinity maturation to produce high-affinity Igs [102]. Five isotypes exist of Igs in
most mammals (IgM, IgG, IgA, IgE, and IgD) that differ in the Fc region of the molecule.
IgM/IgD are associated with development and are the first expressed on B cells as they
leave the bone marrow. Plasmablasts that only express IgD are linked to respiratory
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commensals and pathogens, as well as contradictory reports claiming roles in tolerogenic
pathways or protection from tolerance [103, 104]. IgA is the main isotype found in mucosal
surfaces including gut, respiratory tract and urogenital tract [105], while IgG is the major
serum isotype and can cross the placental barrier to provide fetal immunity [106]. Antigenspecific Igs elicit protection through activation of the complement system, pathogen
neutralization, phagocytosis of apoptotic cells, induced cytotoxicity, and priming of
immune cells [107]. Natural Igs have gained increased attention with protective roles
shown in viral, bacterial, fungal, and parasitic infections [108]. However, these Igs are
considered limited in potential breadth by the low amount of SHM detected [109]. Natural
Igs have been implicated as potent inducers of complement [110], and multiple studies
have shown effective viral control can be achieved through natural Igs and complement
[111-113]. In addition to their role of binding antigen, Igs regulate the immune response
by interaction with Fc receptors (FcRs) [107] which is discussed in greater detail in Chapter
2. T cells are also known to play a role in the antiviral immune response by killing virusinfected cells [114] as well as helping promote B cell responses [115].
Resistance and tolerance

Resistance and tolerance are often described as two distinct defense strategies to
infectious diseases [116]. While resistance is thought to be dependent on the ability of a
host to kill an invading pathogen, tolerance is recognized for its role in protecting hosts by
promoting host health. It should be noted that disease tolerance is not the same as
immunological tolerance in which self-reactive T cells are eliminated, although in certain
diseases immune tolerance can be considered a mechanism of disease tolerance [116].
Mechanisms that fall under disease tolerance include host encoded processes that
support the resolution of infection or prevent the onset of immunopathology in host tissues
that are an inevitable consequence of common inflammatory stimuli [116]. Our studies as
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well as others of Chiropteran genomes revealed numerous gene expansions and
theoretical features based on sequences of genes that suggest tolerance in bats to viral
infection [85, 117]. In ERBs, we had observed an expansion of IFN omega (IFNω) genes,
natural killer (NK) cell receptor genes with both inhibitory and activating domains, and a
large number of major histocompatibility complex (MHC) genes encoded outside the
canonical locus [85]. While the expansions of IFNω may aid resistance mechanisms, as
well as other uncharacterized antiviral genes in ERBs, the expansions in NK receptors
and MHC are hypothesized to aid in tolerance by requiring higher activation thus
producing less inflammation [29, 85, 118-120]. These findings include the finding that the
main NK cell receptor in ERBs is NKG2/CD94, which is associated with inhibitory
responses in other species [121, 122]. The expansion of CD94 genes suggests the
possible combinatorial diversity of heterodimeric receptors is large, and since signal
transmission occurs via a conserved residues, additional receptor diversity would likely be
associated with additional capacity to bind ligands or interact differently to the same
ligands [85]. This greater ligand binding diversity could provide better MHC class I
recognition, possibly distinguishing between a pathogens mimics as well as ability to
recognize self [123]. This study also found that the NK cell receptors possessed inhibitory
and activating domains which is unusual in mammals [85]. This paired with an arginine
residue that preferentially recruits DAP10 rather than DAP12 could suggest the activating
receptors are less potent cytokine inducers, as DAP12 is more efficient in cytokine
production induction than DAP10 [85, 124].
These data support a disease-tolerance model in ERBs. We sought to explore this
further by defining additional features of ERB immunity that could support or refute disease
tolerance. Our findings add to the growing body of evidence that ERBs have encoded
processes that likely contribute to the lack of immunopathology observed, as well as
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highlight new features never before described in a species that may add in a myriad of
pathogen responses.
Hypothesis
Multiple immune-related gene families that have undergone expansion in ERBs
compared to humans have been identified including NK cell receptors, MHC class I genes,
and IFN genes [85]. These findings suggested ERBs may have a tolerance for viral
infections resulting in a less-inflammatory response. We aimed to shift the focus to the
adaptive humoral immune response as most of the effort to dissect the antiviral
mechanism(s) was previously focused on innate immunity [29, 117, 125], in part because
of a lack of reagents and protocols. Here we sought to examine three facets of the ERB
Ig response: 1) characterization of ERB loci associated with the humoral immune
response, 2) definition of the B cell receptor repertoire for gene usage and diversity
mechanisms, and 3) mechanistic identification of antigen recognition of ERB antibodies to
MARV. Differences at the germline for Ig genes could prime the response toward
recognition of specific pathogens, while diversity mechanisms and gene usage define
antigen recognition breadth and capacity, and epitope recognition could support
recognition of novel regions not detected in other species. Together we anticipated these
findings would support or refute our previous hypothesis that ERBs have evolved
tolerogenic mechanisms that contribute to an asymptomatic presentation through a less
inflammatory response.
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Figure 1 : Viremia and antibody profiles in ERBs post MARV infection.
Illustration of viral load and antibody titer over 112 days post MARV infection. Viremia
decrease coincides with peak antibody titer and virus is not detectable upon secondary
exposure, while a robust IgG titer is observed.
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Overview of techniques
In order to determine the V(D)J usage, B cell diversity mechanism(s), potential
diversity, and the repertoire to specific pathogens like MARV, we first needed to
reconstruct the IGH locus which contains the germline genes. The previous assembly,
Raegypt2.0, despite being high quality had IGH genes on 21 different scaffolds and
potentially five IgE genes as well as a novel pattern of D-J-D-J genes (Figure 2). To ensure
there were not due to assembly errors from the high repetition in this region, sequencing
reads that span these novel findings was critical. We used a combination of Bacterial
artificial chromosomes [126] and Bionano optical mapping [127] to assemble the locus
which is described in Chapter 2. This locus revealed unique features including an increase
in copy number of IGHV family members associated with viral protection in humans, a
distinctive organization of the IGHD and IGHJ genes within the locus, an expansion of
IGHE genes not before reported in any other species, and distinct in silico putative
functions for the IgE and IgG subclasses. We confirmed these findings with
transcriptomics and proteomics, defined expression and location of each Ig across
multiple tissues in ERBs. Additionally, we also characterized the FcR genes present and
theoretical functionality in the ERB genome as well as other immune mediators such as
complement proteins and pentraxins.
With an accurate and annotated IGH locus we were able to characterize Ig
transcripts and study the V(D)J rearrangement process in ERBs which was previously
unknown and requires reference genes to compare to. V(D)J recombination, gene usages
and somatic hypermutation rate observed in these rearrangement are described in
Chapter 2. B cells were sorted from peripheral blood mononuclear cells (PBMCs), then
RNA was extracted, cDNA generated, ERB Ig-specific primers used to enrich for isotypespecific transcripts, then libraries prepared and quantitated before sequencing and
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analysis. Analysis required filtering of reads, consensus of mate-pairs, and annotation
using our newly defined germline reference set. We found that the ERB has higher somatic
hypermutation in IgM than humans, a larger range of V-D and D-J gaps, and overall less
combinational diversity than humans. We observed preferential usage for certain IGHV,
IGHD and IGHJ genes.
The counterpart to the V(D)J region of an antibody is the epitope recognized. Thus
the region of MARV ERBs recognize was of interest. In Chapter 3 I discuss the use of a
phage display technology known as Domain Programmable Array (DPA) to quantitatively
characterize the epitope recognition profile of ERB Igs for MARV [128]. Previously
developed and tested on NHP sera for EBOV [128], I modified and executed this technique
for multiple bat species including the Schreiber's Bent-Winged Insectivorous bat [36] and
ERBs (In preparation). We found that regions from MARV GP that ERBs is different than
in vaccinated NHPs. More importantly, these unique epitopes coincide with the GP1/GP2
cleavage site, which may contribute to ERBs ability to control MARV.

21

Figure 2: Raegypt2.0 assembly of IGH locus incomplete.
Original assembly placed IGH genes on 21 different scaffolds. Due to the high repetition,
these were unable to be assembled using current short-read assemblers.
*Unpublished. Submitted to Cell.
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Chapter 2:

Novel insights into the humoral response of Egyptian rousette bats

based on immunoglobulin heavy chain locus
Introduction

Bats (Chiroptera) have been shown to host more zoonotic viruses per species than
any other mammal studied and several bat species were identified as the natural
reservoirs of dangerous zoonotic human pathogens [7-9]. Thus, understanding how bats
successfully withstand viral infections that are highly pathogenic and/or lethal in humans
has become a significant area of research. Recently, we and others has sought to address
this question by examining the genomes of relevant reservoir bat species to uncover
factors that could contribute to natural resistance to viral infections [29, 85, 129]. In some
bat species, like Pteropus alecto, a potent innate response was proposed as one
successful antiviral mechanisms [130, 131], while in other bat species, like Rousettus
aegyptiacus, tolerance was proposed as the strategy to control viral infection with minimal
inflammation [29, 85]. Moreover, several groups have made important observations
regarding the varied antiviral mechanism(s) different bat species employ, mainly on the
innate immunity space (reviewed in [117]).
A member of the Yinpterochiroptera suborder, the Egyptian rousette bat is a known
reservoir for MARV, RAVV, and SOSV [21, 30]. While ERBs display no overt disease
manifestation upon infection with MARV, humans and several non-human primate (NHP)
species present with a severe hemorrhagic fever and high lethality [31]. We previously
reported multiple immune-related gene families that have undergone expansion in ERBs
compared to humans including natural killer cell receptors, MHC class I genes, and
interferon genes [85]. The evaluation of the theoretical function of these expanded genes
suggests that a tolerogenic immune state may exist in ERBs, which allows these animals
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to asymptomatically control viral infections. Here, we expand our previous work by
examining the ERB genome loci associated with the humoral immune response and
investigate whether their putative functionality may also contribute to a tolerogenic
immune state.
Little is known about the generation of specific antiviral immunoglobulins (Igs) in
ERBs. However, when exposed to MARV, ERBs mount a humoral response that can
promote protection [88, 132] and appears not to be mediated by virus neutralization [133].
These observations suggest that other humoral immune mechanisms of viral control for
MARV could favored in ERBs. Igs can interact with other immune mediators like Fc
receptors (FcRs) and/or complement to mediate viral clearance and opsonization. The
ability of the Igs to interact efficiently with those mediators is dictated by the Ig
isotype/subclass. Most mammalian Igs arise from the tetramerization of two identical Ig
heavy chains (IGH) with two identical Ig light chains (IGL) [134]. The IGH locus comprises
numerous variable (IGHV), diversity (IGHD), and joining (IGHJ) genes, as well as constant
(IGHC) genes, that recombine to form the IGH chain of an Ig. The genetic diversity and
copy number of IGHV, IGHD, and IGHJ genes contributes to antigen recognition breadth
and varies widely between species [135]. The V(D)J genes of the IGH and the associated
IGL comprise the fragment antigen binding (Fab) region and is responsible for epitope
recognition. The effector function of the Ig is mediated by the fragment crystalline (Fc)
region encoded by IGHC genes. In mammals, IGHC genes are represented by five
isotypes; IgD, IgM, IgG, IgA, and IgE, however, the number and type of
isotypes/subclasses are not constant across species [136]. For example, humans and
mice have one functional copy of IgM, IgD and IgE and four IgGs. In contrast, mice have
a single IgA while humans have two. Moreover, despite both species containing the same
number of IgG genes, mouse and human IgG subclasses are not functionally equivalent
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[137]. The European rabbit is a striking example of the Ig diversification having one copy
of IgM, IgG and IgE and 13 IgA genes [138]. Within Chiroptera there is transcriptomic
evidence of IgM, IgA, IgE and IgG expression, and IgD is only found in Yangochiroptera
but not Yinpterochiroptera [139-142]. IgG subclass number can range from only one copy
detected (Carollia perspicillata) to up to five (Myotis lucifugus) [141]. However, given the
complexity and repetitiveness of the IGH locus, no accurate description, gene
organization, or annotation has been completed for any bat species.
The Ig Fc region functionally links the humoral adaptive immunity mediated by B
cells with several innate components of immunity like natural killer (NK) cells, monocytes,
macrophages, granulocytes, as well as with complement (reviewed in [101]. Downstream
immune processes are primarily mediated by protein-protein interactions of the Ig Fc
region with FcRs or complement [136, 143]. FcRs modulate the immune response by
delivering activation or inhibition signals to effector cells [136, 144]. FcRs have
characteristic expression patterns among the various leukocyte populations and can bind
specific Ig isotype(s) with varied affinities depending on the amino acid sequence and Nglycosylation status of the Fc region [145]. The complex evolutionary relationship between
FcRs and Ig isotypes/subclasses has resulted in varied FcRs presence/absence among
different vertebrate lineages. Tetraploidization and chromosome doubling has been the
driving force for Ig-domain containing protein expansion and evolution, including FcRs
[146]. Regional duplications were also involved in shaping the FcR repertoire, like the
duplication of the low affinity IgG receptor resulting in FcγRIIC and FcγRIIIB in humans.
Another example of the plasticity of the FcR repertoire in different animals is the high
affinity Fc receptor for IgA (FcαRI) found in several placental mammals but not in mouse
[147].
Complement proteins participate in important Ig effector functions, bridging innate
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and adaptive immune systems (reviewed in [98]). C1q interaction with Fc triggers a
cascade of enzymatic reactions resulting in an activation of processes leading to
opsonization, inflammation, or cell lysis. Pentraxins are a key component of humoral
innate immunity as they can recognize microbial moieties to mediate opsonophagocytosis
and inflammation [148]. Pentraxins are well conserved in diverse species ranging from
arachnids to insects and mammals, and evolutionarily predate the establishment of the
adaptive humoral immune system. Recently, pentraxins were also shown to activate
complement by the classical pathway and interact with FcRs expressed on neutrophils
and monocytes to mediate phagocytosis [149].
Innate immune responses are the first barrier of defense when a microorganism
enters the body until the adaptive immune responses establishes long-term protection. To
understand how bats are asymptomatic to viral pathogens that cause severe disease in
humans, a complete description of the bat’s immune system is needed, including the
innate, adaptive and interphase between both immune systems. To characterize the
humoral immune components in ERBs, we used a combination of molecular biology and
sequencing technologies that allowed us to describe and annotate one contiguous ERB
IGH locus. Completion of the locus revealed unique features including an increase in copy
number of IGHV family members known to act in viral protection in humans; an expansion
of IgE genes with different tissue expression pattern and theoretical functions; and
distinctive in silico putative functions and structural characteristics of the four IgGs found.
The description of the FcR gene repertoire and its theoretical characteristics allowed us
to observe that ERB lack the expansion of FcR for IgG (FcγR) observed in primates; thus,
lacking FcRs with ITAM motif embedded in the cytosolic tails. Moreover, the high affinity
ERB FcγR (FcγRI) present a structure liked to decrease affinity for IgGs. Finally, we
observed the complete absence of functional short pentraxins, proteins that participate in
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the acute phase of resistance against pathogens. Together, our data reinforce the idea
that ERBs might establish a tolerogenic state to surmount pathogenic infections. Our
observations highlight the novelties and uniqueness of the Chiropteran genomes [150,
151] and provide a strong argument for the continued characterization of relevant reservoir
species.
Methods
BAC identification and purification
Bacterial artificial chromosome (BAC) libraries were created from ERB liver tissue
(captive colony at Friedrich-Loeffler-Institut, Germany from ancestor individuals that were
brought to Europe in the 1960s) supplied to a commercial vendor (AMplicon Express). To
isolate BACs of interest we screened BAC libraries using a polymerase chain reaction
(PCR) scheme. Forward and reverse primer pairs unique to single contigs that would
result in ~1100-1600bp amplicons were created. Primers were developed to amplify
regions

at

distal

ends

of

contigs

NW_015493306.1,

NW_015494929.1,

NW_015493824.1, and NW_015493956.1 (Figure 2). Pools of BACs were screened using
these primer pairs resulting in the identification of a single BAC. Due to the overlap of
some BACs a single primer pair could identify more than one BAC clone, in these cases
both BACs were used.
Once identified, BACs were picked from 384-well plates and grown in 250mL of
2X YT broth in the presence of 12.5ug/mL Chloramphenicol for 18-24 hours. BACs were
isolated from cultures using the QIAGEN Plasmid Maxi kit following the manufacturer’s
recommendations. Purified nucleic acids were then subject to Pacific Biosciences library
preparation and sequencing.
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PacBio BAC sequencing
Isolated BAC DNA was sheared to ~20kb average size using needle shearing.
After shearing, DNA damage repair and end repair was performed, followed by ligation of
hairpin adapters resulting in a SMRTBell template. SMRTBell templates were subject to
ExoIII and ExoVII treatment to remove unligated products. Size selection was performed
on Blue Pippin system (Sage Sciences, Beverly, MA) using 0.75% dye-free agarose gel
cassette, marker S1 and Hi-Pass protocol; low cut was set on 4000 bp. Final library
assessment was obtained by Qubit dsDNA BR assay. Individual BACs were barcoded
using 7bp barcodes and sequenced using the Sequel sequencing kit v2.1. Annealing of
sequencing primer and binding polymerase 2.0 to the SMRTbell template was performed
according to PacBio calculator and polymerase/template complexes were loaded onto
SMRT cells (SMRT Cell 1M v3 Tray) via diffusion at a final concentration of 8pM. Libraries
were sequenced with 600 min movies on PacBio Sequel instrument (Pacific Biosciences,
Menlo Park, CA). BACIg4 was sequenced as described except we used a SMRT Cell 1M
v3 LR Tray and sequenced with 1200 minute movies. Upon completion of sequencing
fastq files from each individual BAC were downloaded from SMRT Link and assembled
using the long read assembler Canu [152] and an in house script for BACIg1, BACIg2,
BACIg3. For BACIg4 we used the HGAP4 assembler which is embedded within the SMRT
Link suite using default settings except the “Genome Length” was set to 250kb and the
‘Minimum Subread length’ was set to 8kb. After assembly all sequences were subject to
the ‘Resequencing’ function of SMRTLink which uses all of the reads from a sequencing
run to correct errors present in the final assembly. Resequencing also indicates the
average read depth of each assembly. BACIg1 was sequenced with an average coverage
of 524x and a concordance of 99.99%, BACIg2 at 501x average coverage and a
concordance of 99.98%, BACIg3 at 485x average coverage and a concordance of
99.98%, and BACIg4 at 370x average coverage and a concordance of 99.99%.
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BAC Assembly
Upon completion of sequencing fastq files from each individual BAC were
downloaded from SMRT Link and assembled using the long read assembler Canu [152]
for BACs BACIg1, BACIg2, and BACIg3. For BACIg4 we used the HGAP4 assembler which
is embedded within the SMRT Link suite. Each assembled BAC was subsequently
uploaded to SMRT Link and subject to ‘polishing’ using the embedded ‘Resequencing’
program. BACs were polished using reads that were used for their original assembly.
Completed BAC sequences were uploaded to Geneious. BACIg1-3 were assembled using
the ‘De Novo Assembly’ function. BACIg1/4 were assembled using the ‘Map to Reference’
function using BACIg1 as a reference sequence. The final assembly is represented as
complete sequences from BACIg3, BACIg2, and a partial sequence of BACIg1 (Figure 3).
The near perfect alignment amongst these three BACs likely represents a single
haplotype. For the overlap sequence between BACIg1 and BACIg4 all BACIg1 sequence
(Figure 3, dotted line) was replaced with BACIg4 sequence. These two BACs likely
represent alternative haplotypes and thus the completed ERB IGH locus is a hybrid where
all constant genes are representative of one haplotype and all V(D)J genes are
representative of the alternative haplotype.
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A

B

C

Figure 3 : Assembly and co-localization of BACs.
(A) Geneious ‘De Novo Assembly’ assembly of BACIg1-3. (B) Geneious ‘Map To
Reference’ assembly of BACIg1 set as reference sequence and BACIg4. (C) Organization
of BACs used in the final sequence assembly and relative location of V, D, J, IGH, and
flanking genes in the final assembly. The dotted line indicates the overlap sequence
between BACIg1 and BACIg4. Only sequence from BACIg4 was used in the final
assembly.
*Unpublished. Submitted to Cell.
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Annotation of constant genes
All annotated IGH constant genes were downloaded from Raegyp2.0 using the
NCBI genome browser (Table 3). Coding sequences (CDS) were extracted and mapped
against the completed IGH locus using the annotate function of Geneious. Complete
coding sequences were renamed for ease of discussion (Table 3); for example the
annotated IgE on contig NW_0145493306.1 is labeled as ‘Ig epsilon chain C region-like’
and bears the locus tag ‘LOC107506273’ and was subsequently renamed to ‘IgE_3306’
(bearing the gene name and final four numbers of the contig designation number).
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Table 3 : IGHV genes present on Raegypt2.0

V gene Annotation Raegyp2.0
Scaffold
NW_015493306.1

NCBI
1

NW_015493547.1

6

NW_015493575.1

5

NW_015493590.1

8

NW_015493682.1

5

NW_015493749.1

5

NW_015493769.1

10

NW_015493770.1

2

NW_015493822.1

5

NW_015493830.1

2

NW_015493970.1

2

NW_015494112.1

2

NW_015494214.1

1

NW_015494338.1

1

NW_015494352.1

1

NW_015494409.1

1

NW_015494440.1

1
58
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IgE annotations
NCBI annotated four genes as IgE in Raegyp2.0 and all sequences contained one
or two misannotated exons upstream of the canonical constant heavy 1 (CH1) exon.
These misannotated exons were discarded when determining IGH constant gene
annotation. Only IgE_4929 CDS contained a complete open reading frame with no
premature stop codons, however, it did not contain the final two exons constituting the
transmembrane domains. IgE_3306/3956/3824 contained only minor mutations (<3 indels
per sequence) that resulted in premature stop codons, however, they did contain
annotated TM domain exons. Given these minor changes we were confident that the
usage of all four sequences for annotating the CDS in RaegypIGH3.0 would yield accurate
results. Sequences (Table 3) were uploaded to Geneious and aligned to RaegypIGH3.0
using the ‘Annotate from function’ with a mapping requirement of 75% identity. Five IgE
genes were identified. Annotated exons for each IgE gene were inspected in the context
of RaegypIGH3.0 to ensure that exon/intron sequence rules were maintained. No
adjustments to exon/intron lengths were necessary. Exon sequences from each gene
were then extracted and concatenated to form the final CDS. pIgE1, 2, 3, all contained
indels introducing stop codons into the sequence, whereas the CDS for IgE1, 2 were
complete and contained no premature stops.
IgG annotations
NCBI annotated five genes as IgG in Raegyp2.0. Two annotated IgG
(IgG_3824_TM, IgG_4929) were only partial genes as they resided at the end of contigs.
Complete IgG genes all contained missannotated exons upstream of the CH1 exon. These
misannotated exons were discarded when determining IGH constant gene annotation.
Only IgG_3306 CDS contained a complete open reading frame with no premature stop
codons. The remaining IgGs contained minor mutations (2-6 indels per sequence) that
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resulted in premature stop codons. Given these minor changes we were confident that the
usage of all five sequences for annotating the CDS in RaegypIGH3.0 would yield accurate
results. Sequences (Table 3) were uploaded to Geneious and aligned to RaegypIGH3.0
the ‘Annotate from function’ with a mapping requirement of 75% identity. Four IgG genes
were identified. Annotated exons for each IgG gene were inspected in the context of
RaegypIGH3.0 to ensure that exon/intron sequence rules were maintained. No
adjustments to exon/intron lengths were necessary. Exon sequences from each gene
were then extracted and concatenated to form the final CDS. All four IgG genes contained
complete open reading frames.
IgM/IgA annotations
NCBI annotated a single IgA and IGHM in Raegyp2.0. Both sequences contained
missannotated exons upstream of the CH1 exon, however both CDS contained complete
open reading frames with no premature stop codons. Sequences (Table 3) were uploaded
to Geneious and aligned to RaegypIGH3.0 using the ‘Annotate from function’ with a
mapping requirement of 75% identity. Annotated exons for each IgE gene were inspected
in the context of RaegypIGH3.0 to ensure that exon/intron sequence rules were
maintained. No adjustments to exon/intron lengths were necessary. Exon sequences from
each gene were then extracted and concatenated to form the final CDS. Both IGHM and
IgA contained complete open reading frames.
Annotation of IGHV, IGHD, and IGHJ genes
Raegypt2.0 scaffolds and the final RaegypIGH3.0 assembly were annotated using
IMGT-LIGMotif using all databases. Annotations were manually inspected to confirm RSS
elements reported. Finally, sequences were extracted and BLAST against the
transcriptomic read set described above to confirm unique expression. Reads that
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mapped to an IGHV or IGHJ gene were then annotated with IMGT-HighVQuest to confirm
IGHD annotations, as they may be missed in BLAST due to their small size.
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Table 4 : IgE and IgG characteristics
Tissue
expression
IgE1

Transcriptomic
expression

Proteomic
peptide

# of C
in the
hinge
NA

CXXC LLGG N-Gly
motif motif (Asn297)

Extra
N-Gly

Bl, Sp, LN,
NA
NA
NA
NA
Yes
Te
Shared
peptide
IgE2
Bl, Sp, LN,
NA
NA
NA
NA
NA
Yes
BM, Lu, Te
IgG1 Bl, Sp, LN,
At
Unique
BM, Lu,
Yes
6
CPRC LLGG Present the
peptide
Te, Kd, He
hinge
IgG2 Bl, Sp, LN,
Unique
At
BM, Lu, Te,
Yes
1
--RS LPGG Present
peptide
CH2
Br, Kd,
IgG3 Bl, Sp, Te,
At
Yes
Undetected
1
--RS LPGG Present
Br
CH2
IgG4 Bl, Sp, LN,
BM, Lu,
Unique
Yes
2
--RC LPGG Present
No
Te, Kd, He,
peptide
Li
Bl: blood, Sp: spleen, LN: lymph node, BM: bone marrow, Lu: lung, Te: testes, Br: brain, Kd: kidney,
He: heart and Lv: liver. BOLD FONT: >0.6 normalized log reads, REGULAR FONT: <0.6 normalized
log reads. IGHG gene features reported but not applicable (NA) to IGHE genes.
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Gene ontology for function prediction
COFACTOR is an in silico protein function prediction algorithm that employs three
complementary approaches to surmise protein features [153]. The protein sequence is
analyzed through three pipelines: 1) structure-function database (BioLiP) where gene
ontology GO is predicted by structure, enzyme commission prediction, and ligand binding
site prediction, 2) Sequence-function database (Uni-Prot-GOA) where GO is predicted by
sequence, 3) protein-protein interaction function database (STRING) where GO is
predicted by PPI. COFACTOR requires a PDB (protein database) structure and so we
generated homology models using Phyre2. For IgA, IgM, and IgE composite models were
used and for all IgGs the template with the highest confidence (in this case all 100%), and
the highest percent identity was selected.
Tissue expression and visualization
Reads from ERB tissues previously published [154] were aligned to genes of
interest using the pseudo aligner Kalisto [155]. Transcripts per million were log
transformed and normalized to GAPDH. Heatmaps were created using the R package
pheatmap [156].
Positive selection analysis
Nucleotide sequences were codon aligned using muscle in Geneious. Alignments
were then trimmed to the first in-common, in-frame, codon to maintain open-reading
frames for each species. Final stop codons were removed and edges trimmed to a multiple
of three. Alignments were exported as phy files. Double spaces were added between
sequence names and sequences, and all dashes replaced with N. The alignment was
uploaded into EasyCodeML along with a Newick tree based on individual alignments.
Each sample was run on the branch-site model to detect individual residues and branches
under selection based on LRT values.
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Animals
There are challenges to studying the humoral response of ERBs to MARV. First,
in contrast to mice, these animals are not commercially available and are not inbreed, nor
do genetically modified strains exist. There are currently only three institutes in the world,
the CDC [157], the National Institute for Communicable Diseases of the National Health
Laboratory Service (South Africa), and the Friedrich-Loeffler-Institut (Germany) with ERB
colonies for research. For the proposed work we are continuing to collaborate with the
CDC, which houses their colony of ERBs in a biosafety level 3 (BSL-3) facility. In addition,
all MARV work has to be done at biosafety level 4 (BSL-4). The biocontainment burden
lengthens the amount of time assays take, and requires significant funding for those
trained to perform the work. Further, conducting animal studies in biocontainment severely
restricts the number of subjects, volume of samples that can be obtained, and ability to
repeat these assays independently. To ameliorate some of these restrictions, we have
tested the inactivation of sera from biocontainment and found no detectable difference in
activity post inactivation. We have also collaborated with the Lubee Conservatory to
receive peripheral blood mononuclear cells (PBMCs) from ERBs in captivity for cell
purification. These collaborations ensured a source of cells without the biocontainment
constraints, which will allowed us to delegate studies between our teams and minimized
the biocontainment work necessary. RNA was isolated from three healthy ERBs
maintained at the CDC. Research was conducted under an IACUC approved protocol and
complied with the Animal Welfare Act, PHS Policy, and other Federal regulations and
statues relating to animal experiments. The work was conducted at an accredited facility
by the Association for Assessment and Accreditation of Laboratory Animal Care,
International and adhered to the principles in the Guide for the Care and Use of Laboratory
Animals, National Research Council, 2011.
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Results
Sequencing and assembly of locus
Our first goal was to obtain an accurate gene organization and annotation of the
ERB IGH locus. The high-quality assembly ERB genome (Raegyp2.0) [85] contained
annotated IGHC genes on four contigs: NW_015493306.1, NW_015494929.1,
NW_015493824.1, and NW_015493956.1 (Figure 2). Contig NW_015494929.1 (~1.36
Mb) contains a single copy of an IgA gene (IGHA) upstream TMEM121 which also flanks
IGHA in the human IGH locus, suggesting human and ERB loci are orthologous and that
this contig represents the 3’ end of the locus [158]. The 5’ portion of the ERB IGH locus
was found on Contig NW_015493306.1 (~144kb) containing a single IGHV gene and an
IgM gene (IGHM). We reasoned that these two contigs represent the boundaries of the
IGHC genes and predict that it is distal on an ERB chromosome orthologous to human
chromosome 14q [159]. Several complete or partial IgE (IGHE) and IgG (IGHG) genes
were found distributed among the four contigs, one of those labeled as a pseudo IgE gene
(Figure 2). Annotated IGHV genes were present on 17 contigs (Table 3) and no IGHD or
IGHJ genes were annotated.
Despite the increasing quality of newly published mammalian draft genomes the
repetitive structure of some genomic regions continues to hinder contiguous and complete
genome assemblies [160]. To overcome this limitation, we utilized bacterial artificial
chromosomes [126]. Noteworthy, the ERB tissue used for the BAC library generation was
of different origin (see methods) than that used to construct the original Raegyp2.0
genome [85]. Pools of BACs were screened by PCR and we identified four BACs, BACIg1
to BACIg4. BACs were sequenced using Pacific Biosciences long read sequencing,
assembled, and compared to the Raegyp2.0 genome by using NCBI’s Basic Local
Alignment Search Tool (BLAST). All four BACs mapped to portions of the four contigs
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above as well as the 17 contigs containing IGHV genes. We assembled BACIg1, BACIg2
and BACIg3 resulting in a contig of 474,666 bp (Figure 3). BACIg1/BACIg2 overlap
(~32kb) is 100% identical and BACIg2/BACIg3 overlap (~20kb) contains only two single
nucleotide deletions (present in BACIg2). These data strongly suggest that these three
BACs represent the same haplotype. BACIg4 overlapped with BACIg1 (~61kb) but had a
pairwise identity of 96.5% (Figure 3), suggesting that BACIg4 represents the alternative
haplotype. Due to the relatively low pairwise identity at the BACIg1/BACIg4 overlap, a
consensus sequence was not created at the overlap, and the final IGH assembly, named
RaegypIGH3.0, contains the entirety of BACIg4 sequence and the consensus sequence
of the assembled BACIg1-3 (Figure 3). At one end, RaegypIGH3.0 (634,142 nucleotides)
extends into what is likely a sub-telomeric repeat region while at the other, to genes
normally flanking the IGH locus in other mammals including TMEM121, CRIP1, TEDC1
and a portion of CRIP2, and thus expectedly contains the complete IGHV, IGHD, IGHJ,
and IGHC gene repertoire.

RaegypIGH3.0 links together

Raegpy2.0

contigs

NW_015493306.1 and NW_015494929.1 and adds ~54kb of intervening sequence.
Bionano Optical Mapping data demonstrated that contigs NW_015493306.1 and
NW_015494929.1 are separated by ~56kb of sequence (data not shown). The other two
Raegyp2.0 contigs (NW_015493824.1, and NW_015493956.1) that contain IGH genes
likely represent missasembled portions of the newly sequenced 54kb intervening
sequence.
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Annotation and description of IGHV, IGHD and IGHJ genes
In Raegyp2.0 58 IGHV genes present on 17 contigs were annotated by NCBI’s
pipeline (Table 3). Within RaegypIGH3.0 we were able to annotate 66 IGHV genes using
IMGT/LIGMotif (Figure 4) [134]. Of those 66 IGHV genes, ten are pseudo genes and one
(IGHV6-1.1) appears to be truncated. All IGHV genes have common conserved amino
acids (C23, W41, C104) as identified by IMGT/LIGMotif. Similar to what has been
observed in other pteropid bats, IGHV genes represent all three V clans (based on human
subgroupings: clan I: IGHV1/IGHV5/IGHV7; clan II: IGHV2/IGHV4/IGHV6; and clan III:
IGHV3) and include the families IGHV1, IGHV3, IGHV4, IGHV6 and IGHV7 (Figure 5)
[139, 161]. They are on average 301 nt +/- 31 nt long (excluding the truncated IGHV6-1.1)
which is similar to what is reported in other mammals (Figure 6) [134, 161]. Additionally,
65 IGHV genes contained downstream recombination signal sequences [162] were
identified by IMGT/LIGMotif, with only one pseudogene (VH1-2.1) lacking one (Figure 5).
No IGHD or IGHJ genes were annotated in Raegyp2.0 by NCBI. We examined
RaegypIGH3.0 using IMGT/LIGMotif and identified eight IGHD and nine IGHJ genes
(Figure 4) which included IGHD genes comprising the IGHD1, IGHD2, IGHD3, and IGHD6
families. ERB IGHD genes are 17-37 nucleotides in length similar to human IGHD genes,
which vary from 11-37 nucleotides in length (Figure 6) [161]. All IGHD genes contained
upstream and downstream RSS sequences (Figure 5). The nine IGHJ genes identified
comprise the IGHJ2 (two genes), IGHJ4 (six genes), and IGHJ5 (one gene) families
(Figure 5). ERB IGHJ genes range between 40-58 nucleotides in length, slightly smaller
on average than what is reported in humans (48-63 nucleotides) (Figure 6) [161]. All IGHJ
contain functional RSS with the exception of the two IGHJ2 genes (Figure 5). Both IGHJ2
genes contain impaired heptamers, 5’-GAGCGGG-3’ instead of the conserved 5’GAGCGTG-3’, observed in all human IGHJ gene heptamers. Moreover, all IGHJ genes
from the IGHJ4 and IGHJ5 families retained the highly conserved WGXG amino acid motif,
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while IGHJ2.1 (WCRG) and IGHJ2.2 (WGEA) do not (Figure 5) [163]. Thus, it is likely that
the IGHJ2 genes are not functional and not utilized in recombination. As has been
observed with other mammals, we identified variation in the N-terminus of IGHJ genes
and high conservation in the C terminus. One intriguing observation was the IGHD-IGHJIGHD-IGHJ organization within the IGH locus (Figure 4). This observation is similar to a
duplication event previously described in the bovine (Bos taurus) draft genome [164].
After annotating the IGHV, IGHD and IGHJ genes, we wanted to determine if these
genes are expressed. Mining previously published transcriptomic data derived from ERB
lymph node to identify V(D)J containing transcripts by BLAST against RaegypIGH3.0.
Recovered reads were annotated by IMGT [85]. The annotated reads were then remapped
to RaegpyIGH3.0 to confirm location and expression of annotated genes. We were able
to validate the expression of the majority of IGHV genes annotated as functional. Very
limited transcriptome support was detected for any of pseudogenes and the truncated
IGHV6-1.1. We also identified transcriptomic evidence for all IGHJ genes (Figure 7).
Notably, >30 fold fewer transcripts mapped to the two IGHJ2, and IGHJ4.1 genes which
is consistent with our supposition that the IGHJ genes in the first cluster might not
incorporate in mature Igs (Figure 4, Figure 7). As IGHD genes are small and difficult to
identify by BLAST, we used reads that were annotated with an IGHJ gene and annotated
them with IMGT-HighVQuest. This method was able to further confirm all eight IGHD
genes.
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Figure 4 : IGHC locus representation
Complete assembly of the IGH locus (RaegypIGH3.0). Genes are placed relative to their
location within the entire assembly and the locus spans ~573kb.
*Unpublished. Submitted to Cell.
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Figure 5 : Genome annotation of V(D)J genes.
(A) IGHV phylogeny of functional genes. Amino acids were aligned with ClustalW and then
a tree created in Geneious using Bayes. Genes cluster within defined clans I, II and III.
(B) IGHV recombination signal sequences. (C and D) IGHD recombination signal
sequences. (E) IGHJ recombination signal sequences. (F) Amino acid alignment of IGHJ
genes with conserved WGXG motif (boxed) and residues that could impair functional
products (underlined) indicated.
*Unpublished. Submitted to Cell.
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Figure 6 : Length distribution of IGHV, IGHD, and IGHJ genes.
Nucleotide lengths for ERB IGHV genes (A), IGHD (B) and IGHJ (C) contained on the IGH
locus (RaegypIGH3.0), ordered from 5’ to 3’. Pseudo genes shaded gray, functional in
black.
*Unpublished. Submitted to Cell.
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Figure 7 : V/J gene counts from transcriptomic data.
ERB IGHV and IGHJ genes were BLAST against transcriptomic reads from ERB lymph
node. A) IGHV genes and B) IGHJ genes where count A is the sum of the count of reads
and if a read mapped to multiple genes is split between all hits and where count B is
unique reads that only map to that gene. C) Representative example of a read which a
IGHD (highlighted) and IGHJ (underlined) gene identified.
*Unpublished. Submitted to Cell.
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Annotation and description of IGHC genes
To identify RaegypIGH3.0 IGHC genes, we downloaded NCBI annotated IGHC
sequences from Raegyp2.0 and performed a BLAST search against RaegypIGH3.0. The
annotation of each gene was inspected to ensure that exon/intron rules were followed.
The most 5’ IGHC gene of the locus is a single IGHM followed by a repeating structure of
IGHE and IGHG, and ends with a single IGHA (Figure 4). Like some pteropid bats, we
were unable to identify an IGHD gene in ERBs [139]. In contrast to all other mammals
studied thus far we identified five IGHE genes in RaegypIGH3.0 [165]. The first three IGHE
genes contain indels that result in the introduction of stop codons in all three forward
reading frames. Thus these three genes are likely unprocessed pseudogenes (Figure 4).
The last two IGHE genes contain complete open reading frames and thus are putatively
functional; making ERBs the only species identified to date that contain more than one
putatively functional IGHE gene. Similar to what has been observed in mice and humans,
the ERB contains four IgG genes and all four contain complete open reading frames and
are putatively functional.
Given the quality of the assembly and the fact that open reading frames for all IgG,
IgA, IgM genes, and two of five IgE genes were complete and required no additional
sequence manipulation on our behalf we are confident in the accuracy of our annotation.
IgE and IgG genes are numbered based on their position in a 5’ to 3’ orientation with the
telomeric end representing the 5’ end (Figure 4). To determine the sequence identity
among the IgE and IgG genes we performed nucleotide and amino acid alignments using
ClustalW (Figure 8, Figure 9). At the amino acid level the pairwise identity between the
four IgG genes is 89%, and between IGHE1 and IGHE2 is 94.4% while at the nucleotide
level they had pairwise identities of 91.9% and 97.8%, respectively. Consistent with
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previous observation in other species, the majority of the IGHG sequence heterogeneity
is clustered at the hinge and CH2 domains [162].
We used our previously published transcriptomic data to verify the expression of
the different IGHCs found in RaegypIGH3.0 [154]. Raw reads were mapped by BLAST
against the coding sequence of each IGHC gene. Unique reads specific to a single isotype
or subclass were identified. Finally, we also performed mass spectrometry on protein A/G
purified total sera collected from wild-caught ERBs to verify levels of expression (Table 5).
Using a custom database of tryptic peptides based of on the coding sequences defined
here, we were able to detect unique peptides corresponding to IgG1, IgG2, IgG4, IgM and
IgA. Remarkably, we were also able to detect an IgE peptide (shared by IgE1 and IgE2),
but not IgG3 in serum. These data demonstrate that mRNAs derived from the identified
genes are translated and confirms the presence of multiple IgG subclasses, IgA, IgM, and
IgE.
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Figure 8 : IGHE gene alignments with reads.
Alignments of reads from RNA-seq data sets demonstrating the association of private
SNPs with specific immunoglobulins. Yellow highlight denotes the unique SNP in identified
in the read(s) (numbered rows) and the immunoglobulin (top row). Red highlight denotes
SNPs present in the reads that are not present in the immunoglobulin.

*Unpublished. Submitted to Cell.
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Figure 9 : IGHG gene alignments with reads.
Alignments of reads from RNA-seq data sets demonstrating the association of private
SNPs with specific immunoglobulins. Yellow highlight denotes the unique SNP in identified
in the read(s) (numbered rows) and the immunoglobulin (top row). Red highlight denotes
SNPs present in the reads that are not present in the immunoglobulin.
*Unpublished. Submitted to Cell.
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Table 5 : Protein sequences used to identify immunoglobulins by Mass
Spectrometry.
SEQUENCE
WLHGNQELSR
VNYLGTIIEDHAR
PSVTCVVVDVSQDDTDVK
IVSTLEINHR
ATGPIQEPQVYVLAPHPDELAK
GFSPSDVFVQWMQR

*Unpublished.

IMMUNOGLOBULIN
IgA
IgE
IgG1
IgG2
IgG4
IgM
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IGHC genes evolutionary relationship
As expected, ERBs IGHC genes are most closely related to members of
Yinpterochiroptera than of Yangochiroptera. Our data bolster previous reports of IGHC
clustering within Chiropteran suborders (Figure 10) [166]. While ERB IGHM is basal to
Cynopterus sphinx and both pteropid bats included in our analysis, Cynopterus sphinx
IGHA and IGHE are basal to ERB and both pteropid bats IGHA and IGHE, respectively.
The relationship of the four ERB IGHGs is unresolved, however, our analyses clearly
demonstrate they cluster within the Yinpterochiroptera clade. All ERB IGHGs and IGHEs
appear to cluster together, demonstrating that the tandem duplication observed occurred
after the demarcation of the species. In summary, our molecular data recapitulate other
taxonomic data demonstrating ERB clusters within Yinpterochiroptera [166].
Functional characteristics of the ERB IGHC genes.
IGHC motifs associated with Ig structure and function had been widely described
in other mammals (Table 4). Ig cysteines are involved in intra- and inter-molecular disulfide
bonds and are crucial for the Ig structure. All the ERB IGHC genes contained at least one
cysteine in the hinge region that would potentially allow for IGH:IGH disulfide bonding to
produce canonical dimeric receptors (Figure 10). The hinge domain of IGHG is known to
be variable at both inter- and intra-specific levels, and crucial to form disulfide bongs
between IGHs [167]. ERB IGHG1 contains a single 5’-CPRCP-3’ motif, which is present,
repeated 4 times, in human IGHG3 (Figure 10). Remarkably, neither ERB IGHG2, IGHG3
nor IGHG4 have the canonical CXXC domain at the hinge that was associated with the
ability to form inter-molecular disulfide bonds between both IGHCs. Moreover, ERB
IGHG2 and IGHG3 lack both cysteines at that domain, the first cysteine is missing and the
second (Cys109) is replaced by a serine.
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Figure 10 : IGHC gene motifs and phylogenies
A) Phylogeny of IGHC genes cluster within isotypes. Note: Human IgA1 was excluded
from the tree. B) Alignment of human (Hs_IgM) and ERB (Ra_IgM) IgM. C) Alignment of
human (Hs_IgE) and ERB IgEs (Ra_IgE1 and Ra_IGE2). D) Alignment of human
(Hu_IgA2) and ERB (Ra_IgA) IgA. Note: Human IgA1 was not aligned. E) Alignment of
human (Hs_IgG1-4) and ERB (Ra_IgG1-4) IgGs. N-Glycosylation sites shown in bold,
disulfide bond Cysteines are shown in blue, and other cysteines are shown in red.
*Unpublished. Submitted to Cell.
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N-glycosylation modulates Ig effector functions, including its interaction with FcRs
and complement. ERB IGHM contains all the N-glycosylation sites homologous to human
IGHM and an additional two putative sites (Figure 10) [168]. Human IGHE contains seven
sites that can be subject to N-glycosylation. Both ERB IGHE1 and IGHE2 share three of
those sites (Figure 10) [168]. However, four N-glycosylation sites present in humans are
missing in ERBs while both ERB IGHE1 and IGHE2 contain two additional putative Nglycosylation sites compared to human. Human IGHA2 contains four N-glycosylation sites
of which only two are conserved in ERB IGHA (Figure 10). Three other sites not
homologous to human are present in ERB IGHA, although the second N-glycosylation site
in ERB IGHA is relatively close to the first site in human IGHA2 and may potentially
perform a similar function [169]. Finally, all four human IGHGs contain a single Nglycosylation site at Asn297 [170], all four ERB IGHGs share that conserved site but ERB
IGHG2 and IGHG3 have one additional putative site (Figure 10). Remarkably, the IGHG1
of ERBs contains the longest hinge domain (23 amino acids) and a putative Nglycosylation site (IGG1 hinge: PVKYTCDRENGSCSCCSACPRCP) not present in the
other ERB or human IGHGs.
The region of the IGHC responsible for making contact with the FcγRI had been
very well characterized [171-173]. Beside the already mentioned N-glycosylation site at
Asn297 three critical contacts have been identified: 1) the lower hinge region
(Leu233Leu234Gly235Gly236); 2) the CH2 BC loop Asp265; and 3) the CH2 FG loop
(Ala327Leu328Pro329Ala330Pro331). All ERB Igs have the conserved Asp265 and the CH2 FG
loop, however, Leu233Leu234 are only present in ERB IgG1 and not in the other subclasses,
where the first leucine is conserved but the second is substituted by a proline
(Leu233Pro234Gly235Gly236). The mutation of these leucines into alanines (LALA mutation)
is associated with the inability of the IgG to bind to FcRs [174].
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Tissue expression of immunoglobulin constant genes
We determined the tissue-specific expression profiles of the identified expanded
IGH subclasses. Using RNA-seq transcriptomic data, reads were first pseudo aligned
using Kalisto to obtain transcripts per million (TPM), log(2) transformed, and subsequently
normalized to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) to obtain level of
expression of each IGHC per tissue (Figure 11). IGHM is expressed in all tissues and
most highly expressed in the bone marrow, lymph node, blood, spleen, and lung. The
highest expression of IGHA is observed in the lungs but low relative expression was
identified across all tissues in a manner consistent with observations in other mammals
[175]. Similar to other mammals, each subclass of IGHG had differential expression with
one subclass being predominant in most sites examined [162]. We observed IGHG1
generally had the highest expression followed by IGHG4, IGHG2, and finally IGHG3
(lowest expressed in all tissues). While IGHG1 is the most highly expressed in lymph node,
spleen, and lung, it was not found in the brain or liver. IGHG2 expression was found to be
highest in the spleen with no expression in the heart and liver. IGHG3 expression was
highest in testes although it was lower than all other IGHGs examined and absent in bone
marrow, heart, kidney, lymph node, liver and lung, which agrees with our inability to detect
protein of this isotype in serum. In contrast, IGHG4 was found in all tissues except brain
and was the highest expressed in spleen. Of the two functional IGHE genes, expression
of IGHE2 was present in lymph node, blood, spleen, and testes whereas IGHE1 was
expressed in those tissues as well as bone marrow and lung. The differential expression
of both IgE genes are highly indicative of a differentiation of function of these genes.
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Figure 11: Tissue expression of ERB Igs
(A) Heatmap of log transformed reads normalized to GAPDH within each tissue: blood,
spleen, lymph node, bone marrow, lung testes, brain, kidney, heart, liver.

*Unpublished. Submitted to Cell.
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Gene Ontology suggests IgE and IgG subclasses serve unique functions
Expansion in IGHG and IGHE genes and the differential tissue expression suggest
a diversification of functions between subclasses. We utilized the COFACTOR [153], an
algorithm built to predict functions based on conserved motifs, to determine putative
functional differences between IGHC sequences. COFACTOR create homology models
and the GO knowledgebase to predict functional differences.
Due to the complexity and diversity of IgG across mammals we restricted our
analysis to just human and ERBs (Figure 12). According to this analysis, the four ERB
IgGs likely perform different effector functions than their human counterparts with no clear
statistically significant functional equivalency between IgGs from both species. Further,
similar to how the genes cluster phylogenetically (Figure 10), the Igs cluster within species
suggesting no clear similarity in predicted functions overall. Strikingly, no cellular
component (CP) Plasma Membrane Part GO term was identified for ERB IgG1 and IgG3,
in sharp contrast with all the human IgGs and ERB IgG2 and IgG4.
IGHE of all mammals examined were predicted to exhibit immune effector process
and classical complement activation functions. Both IGHE1 and IGHE2 are predicted to
be important for the response to other organisms, a key feature of IGHE in other mammals
[165]. But ERB IGHE1 and IGHE2 also exhibit differences that support a possible
diversification of function (Figure 12). While IGHE1 functionality appears to more closely
resemble human, mouse, horse, dog, cow, and pig; IGHE2 predicted function better
mirrors the Myotis lucifugus (Figure 12). The cellular component prediction suggests that
IGHE2 is secreted while IGHE1 is more likely to be membrane bound. Although these
predictions require further validation, they offer insight into the potential functions of these
novel immunoglobulins. Finally, we examined ERB IGHA and IGHM, and found that their
predicted functions are broadly similar to what has been described in human homologues.
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Figure 12 : Predicted functions of ERB Igs
A) Correlated gene ontologies between Human and ERBs IGHG subclasses based on
confidence score. Biological process (BP): GO:0006958, GO:0006910/GO:0006911,
GO:0051707 and cellular component (CC): GO:0044425, GO:0044459, GO:0042571
shown. B) Correlated gene ontologies for IGHE genes between species: ERB (Raeg1,
Raeg2), Pale (Pteropus alecto), Pvam (Pteropus vampyrus), Csph (Cynopterus sphinx),
Mluc (Myotis lucifigus), Mdav (Myotis davidii), Efus (Eptesicus fuscus), Cper (Carollia
perspicilata), Ecab (Equus caballus), Cfam (Canine familiaris), Btau (Bos taurus), Sscr
(Sus scrofa), Mmul (Macaca mulatta), Hsap (Homo sapiens), Mmus (Mus musculus),
Mdom (Monodelphis domestica). Biological process (BP): GO:0006958, GO:0006910,
GO:0051249,GO:0009617, GO:005085 and cellular component (CC): GO:0016021,
GO:0042571 shown.
*Unpublished. Submitted to Cell.
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Identification and expression of ERB FcRs
Given that ERB IgG does not appear to mediate virus neutralization on MARV
infection [133] we investigated functions associated to the Fc region of the Ig mediated by
FcR interactions or proteins from the complement system. FcRs can be expressed either
at the cell membrane or intracellularly. Their number and composition varies between
species [176]. Indeed, the mouse and human genomes contain 11 and 16 FcRs,
respectively [136]. We identified 13 FcRs annotated in Raegyp2.0, the orthologs for
human FCεRI, FCεRII, FCγRI, FCγRIIB, FCγRIIIA, FCμR, FCαμR, FcRn, FCRL4, FCRL5,
PIGR and TRIM21, and a receptor with no-ortholog annotated as FCγRII-like (
Table 6). Fc signaling associated chains were also found in Raegyp2.0 (FCεR1β and
FCεR1γ). However, we did not find orthologs for FCαR, FCγRIIA, FCγRIIC, and FCγRIIIB.
Among ERB FCγRs, one is the canonical inhibitor FCγRIIB containing the
Immunoreceptor Tyrosine-based Inhibition Motifs (ITIM) at the cytosolic tail (Figure 13). In
contrast to human FCγRIIA and FCγRIIC, no ERB FcγRs contain Immunoreceptor
Tyrosine-based Activation Motifs (ITAM) motif embedded in their cytoplasmic tails.
Interestingly, within ERB FCγRI and the FCγRII-like an Asn306 has reverted to an Asp306
(Figure 13). This substitution would still allow for association with the signaling γ chain but
this association would be required for cell surface expression [177]. Moreover, the ERB
FCγRI contains a longer FG loop associated with lower affinity for IgG [173] (Figure 13).
We also determined their specific expression profiles across ERB tissues. All FcRs
were found expressed in at least one tissue; FcRn, as in humans, was the most
ubiquitously expressed (Figure 13) [178]. Detailed studies of the interaction between these
receptors and the corresponding ERB Igs, examination of their expression at the singlecell level, and determination of the mechanism to mediate function will be the focus of
future studies.
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Table 6 : FcRs and associated functions in humans, mice, and ERBs
Receptor
IgA/IgM
FcαR
FcαµR
FcµR
IgG
FcRIa
FcRIIa
FcRIIb
FcRIIc
FcRII-like

Hsap

Mmus

Raeg

Function

Signaling

Yes
Yes
Yes

No
Yes
Yes

No
Yes
Yes

Activation
Phago/endocytosis
Endocytosis

 chain

Yes
Yes
Yes
Yes
N/A

Yes
No
Yes
No
N/A

Yes
No
Yes
No
Yes

Activating
Activating
Inhibitory
Activating
Unknown

Yes
No
No

Activating
Decoy/activation
Activating

 chain (ITAMi)
ITAM (ITAMi)
ITIM
ITAM
Unknown (
chain?)
 chain
GPI
 chain

Yes
Yes

Activation
IgE regulation

Yes
Yes
FcRIIIa
Yes
No
FcRIIIb
No
Yes
FcRIV
IgE
Yes
Yes
FcRIa
Yes
Yes
FcRII
FcR-like
FcR L1
Yes
Yes
FcR L2
Yes
No
FcR L3
Yes
No
FcR L4
Yes
No
FcR L5
Yes
Yes
FcR L6
Yes
Yes
FcR LA
Yes
Yes
FcR LB
Yes
Yes
Others
FcRn
Yes
Yes
PIGR
Yes
Yes
TRIM21
Yes
Yes
Associated/signaling molecules
Yes
Yes
FcBP
Yes
Yes
FcRIβ
Yes
Yes
FcRI

Yes
No
Yes
Yes
Yes
No
Yes
Yes

Inhibitory

Yes
Yes
Yes

Recycling/transport
Transport
Activation/proteasome

Yes
Yes
Yes

Signaling molecule
Signaling molecule

β and  chain

(ITAM)2
ITAM + (ITIM)2
ITAM + ITIM
(ITIM)2
ITAM + (ITIM)2
ITIM
Intracellular
Intracellular

ITAM
ITAM

Summary of FcRs in human, mouse, and ERBs with known functions and associated motifs. Motif
presence in ERBs examined manually after alignment of amino acid sequences in Geneious R11.
*Unpublished. Submitted to Cell.
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Figure 13 : FcR comparison between ERB and other mammals and expression.
A) Alignments of FcR cytosolic domains. ITIM and ITAM motifs are shown. Mmus (Mus
musculus), Raeg (Rousettus aegyptiacus), Hsap (Homo sapiens), Mfas (Macaca
fascicularis) and Mmul (Macaca mulatta). B) FcR transmembrane residues for γ-chain
association and surface expression. C) Alignment of F and G loop of FcRs showing
additional residues in the ERB loop. D) Tissue expression of FcRs in ERBs normalized to
GAPDH for each tissue.
*Unpublished. Submitted to Cell.
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Complement proteins and expression levels
Complement interacts with Ig FcR and participates in several of the Ig effector
functions (reviewed in [98]).The three subunits of the C1q complex, C1qA, C1qB and
C1qC, are present in Raegyp2.0 and are putatively functional. Complement proteins are
primarily synthesized in the liver but a variety of other cells can also produce complement
proteins. Interestingly, C1qA, C1qB, C1qC and C3 are ubiquitously expressed in ERB
tissues supporting the important role these key immune mediators have bridging innate
and adaptive immunity (Figure 14). While C3 is mainly expressed at the Liver and lung,
the C1q proteins are mainly expressed at Spleen, lymph nodes, Liver and lung.
Identification and expression of pentraxins
Beyond Igs, many humoral components of innate immunity can interact with
complement proteins and FcRs. We examined Raegypt2.0 and found no evidence of
functional short pentraxins (C reactive protein (CRP) and serum amyloid P component
(SAP)). Only a pseudogene SAP gene was annotated containing numerous premature
stop codons. We inspected annotated SAP sequences from other published bat genomes
and found they too contained numerous stop codons, suggesting that functional SAP was
inactivated well before the emergence of extant bat species (data not shown). Although
no short pentraxins were detected, we were able to identify several long pentraxins:
pentraxin 3 (PTX3) and PTX4, neuronal pentraxin 1 (NPTX1) and NPTX2 as well as the
neuronal pentraxin receptor (NPTXR). We also identified the mucosal pentraxin (MPTX)
gene which is annotated as a pseudogene in ERBs and humans. We were also interested
in DC-SIGN as it is of the same receptor class as FCεRII and confirmed a human
orthologue present in Raegyp2.0. NPTX1, NPTX2, and NPTXR were found to be highest
expressed in the brain, while PTX3 was found highest in the lung, PTX4 highest in testes,
and DC-SIGN in lymph node (Figure 14).
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Figure 14 : Expression of complement proteins and pentraxins.
Heatmap of normalized log transformed reads for pentraxins and complement proteins
C3, C1QB, C1QA and C1QC. Reads normalized to GAPDH for: liver, lung, spleen, brain,
lymph node [179], bone marrow (BM), testes, peripheral blood mononuclear cells
(PBMCs), heart and kidney.
*Unpublished. Submitted to Cell.
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Positive selection in IGHG, IGHE, and FcRs
We examined IGHC and FcR genes of ERBs to determine whether gene level
evolution could contribute to unique functionalities. We first wanted to ascertain if
receptors or IGHC genes were selected at a gene-level using the branch model [180]. We
found IGHG4 to be positively selected (w=1.24044, LRT=0.0491) while IGHG1, IGHG2,
IGHG3, IGHE1, and IGHE2 under neutral selection (Table 7). We further found no
evidence of branch level positive selection in FcRs.
In addition to whole gene expansions, we were interested in positively selected
residues in ERBs. To this end, we used the branch site and site models to identify any
potentially selected for residues in FcRs and IGHC genes. No residues were found to be
under significant positive selection in the FcRs, however, we did find IGHE2 to have a
positively selected site under the branch site model (LRT=0.01157), namely Ala3. We also
found IGHG4, under the branch site model (LRT= 0.000003176), to have a positively
selected Lys354 at a site that in all other species examined is a serine. These residues and
their importance to ERBs is of interest for future studies.
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Table 7 : Positive selection of IGHG and IGHE residues.
Gene
IGHG1
IGHG2
IGHG3
IGHG4
IGHE1
IGHE2

Omega
0.09324
0.30076
0.30063
1.24044
0.85691
085592

LRT
0.040542015
0.185150251
0.675926128
0.049072014
0.862195588
0.916705202

*Unpublished. Submitted to Cell.
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Discussion
Bats asymptomatically harbor viruses that can cause severe disease in humans
[8, 9, 140]. Even when some bat’s antiviral mechanism(s) have been described (reviewed
in [117]), a comprehensive understanding of the strategy used by bats to overcome these
pathogens remains elusive. It has been proposed that some bat species have a potent
innate antiviral response compared to primates, which allows for early control of virus
replication and ultimately results in development of an effective adaptive immune
response [131]. Alternatively, for other bat species, like ERBs, it was proposed an
enhanced tolerance of infection rather than enhanced viral defense [85]. This model of
viral tolerance is supported by studies of ERBs that result in protracted incubation and
sustained viremia for up to three weeks after infection with limited inflammation post
MARV infection [11, 43]. Here, we dissect components of the humoral immune response
of ERBs that support this letter option resulting in an enhanced tolerance to viruses.
An expanded repertoire of IGHV known to respond to pathogens
So far, most of the efforts to understand the bat anti-viral response were focused
on their innate immunity, mostly due to lack of adequate bat specific reagents to address
humoral and cellular responses of the adaptive immunity. ERBs mount humoral responses
to MARV infection and become refractory to future exposure to the virus [132]. Moreover,
maternal immunity can be transmitted to newborns by breastfeeding [132], [87].
Surprisingly, anti-viral mechanism(s) of protection of ERB humoral immunity seems not to
be mediated by viral neutralization [133]. To be able to better characterize the potential B
cell repertoire diversity and begins to understand the adaptive humoral responses in
ERBs, we first described and annotated the gene germline organization of the IGH locus
resulting, to our knowledge, in the most complete description of any bat species to date.
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We found representatives of all three mammalian IGHV clans (Figure 5),
consistent with findings in pteropid bats [129]. Within these gene clusters, we found that
the IGHV germline of ERBs contains numerous gene expansions relative to human
orthologs (Figure 4). Advances in high-throughput DNA sequencing are enabling the
characterization of the complex B cell repertoire for many animal species uncovering the
existence of common signatures in the response to pathogens. The approach has shown
that different individuals can respond to a given pathogen antigen with V(D)J
rearrangements that share amino acid signatures and are encoded by common IGHV
genes [181, 182]. We observed that several of the ERB IGHV genes present at the IGH
locus, are associated with protective antibody responses against viral pathogens in
humans (Table 8). For example, two human IGHV genes associated with MARV
protection, IGHV4-39 and IGHV4-59 [79], are represented in the ERB IGH locus with one
and eight genes copies, respectively. IGHV4-39 is the IGHV germline for mAb MR191, an
antibody that competes with NPC1 for binding of GP and provides protection to MARV in
NHPs [183]. Human IGHV3-23 was associated with a protective role against Ebola virus
(EBOV) as it is part of the ADI-15878 V(D)J, a pan-filoviral antibody that targets the fusion
loop of GP2 [184] as well as 2.1.1D7 and 2.1.7G7, neutralizing antibodies that target the
GP1/2 interface [185]. ERBs have five functional copies of IGHV3-23 in the IGH locus.
Similarly, human IGHV3.15 was also associated with protective mAbs against EBOV;
ERBs contain a single copy of this gene [182]. The ERB also has two functional copies of
IGHV1-69. Usage of IGHV1-69 had been associated with MERS-CoV [186, 187] Hendra
and Nipah viruses [187], EBOV [188], and influenza virus [189]. Similarly, ERBs contain
IGHV3-21 which has also been demonstrated to confer protection against dengue [190]
and EBOV [185]. IGHV3-74, which is also expanded in the ERB IGH locus, has been
shown to be associated with several viral pathogens, such as Andes Hantavirus [191],
H5N6 avian influenza virus [192], influenza vaccination [193] and Epstein-Barr virus [194].
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On the other hand, IGHV3-13, which has been associated with protective antibodies
against EBOV in humans [185, 188], was not found in the ERB IGH locus. The observation
that several of the IGHV gene associated with protection against diverse viral pathogens
are present and some expanded in the ERB IGH locus, suggests that these animals might
be equipped with an IGHV germline prone to generate antibodies that can bind to the
viruses they host.
The pattern and location of ERB IGHD and IGHJ genes were found to be more
similar to the particular organization observed in cattle than the canonical organization of
most mammals [195]. The IGHV-IGHD-IGHJ-IGHD-IGHJ-IGHC organization at the ERB
IGH locus is certainly intriguing. However, the most 5’ cluster of IGHJ genes is composed
by IGHJ2.1 that has a non-functional RSS (Figure 5) and no transcriptomic support; and
IGHJ4.1 that was the least expressed IGHJ gene in ERBs (Figure 7), which suggests this
IGHJ cluster might not be utilized in the V(D)J rearrangement.
An additional finding at the ERB IGH locus was the expansion of the IGHJ4 gene
to six copies that varied by only a few amino acids in length and nucleotide composition.
Even though in humans IGHJ4 is known to be the most commonly used J segment, the
human IGH locus only contains one copy of this gene [196]. The duplication of the IGHJ4
genes might reflect its important role in V(D)J recombination in ERBs. The contribution of
the IGHJ4 gene to protection has not yet been elucidated in other animals [197] so, the
functional role of the different IGHJ4 copies in ERBs would need to be further addressed.
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Table 8 : IGHV genes with known activities against viruses
IGHV

Functional

Pseudogenes

VH1/OR15-1

9

1

VH1-2

2

1

VH1-8

4

1

VH1-69

2

1

VH3-7

Found in human responses

mAbs

EBOV
Influenza, MERS-CoV, Hendra
and Nipah virus

2.1.6C11
m336, m101,
m102

1

MARV

VH3-15

1

EBOV

MR238
5T0180,
1T0027,
3T0265,
2.1.1D5

VH3-21

1

EBOV

VH3-23

5

EBOV

9.6.3A6
9.6.3D6,
2.1.1D7,
2.1.1G7

VH3-33

3

VH3-48

5

EBOV

2.10.1E6

VH3-71

2

VH3-74

4

VH4/OR15-8

1

VH4-30

1

2

VH4-38

2

1

VH4-38-2

1

VH4-39

1

VH4-59

8

VH4-61

1

VH6-1
VH7-4

Truncated

1

1

1
1

*Unpublished. Submitted to Cell.

MARV

MR191, MR201,
MR209, MR232
MR111, MR114,
MR186, MR241

MARV

MR208

MARV

1
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Expansion of the IGHE - IGHG tandem repeat resulted in two functional IgEs and
four functional IgGs in ERBs
To our knowledge, the ERB is the first species identified thus far to contain more
than one functional IGHE. Although humans contain two copies of IGHE, one of the copies
is a non-functional pseudogene [198]. The tightly regulated IGHE copy number in the
mammalian IGH locus might reflect a balance of a cost/benefit between IgE function and
expression level. It is known that although only one copy is present in humans, individuals
with increased IgE expression can suffer conditions such as hyper-IgE syndrome [199].
The three IgE pseudogenes observed in ERBs might be a direct reflection of tightly
regulated IGHE copy number. It is possible that as IGHE-IGHG tandem gene duplications
occur, selective pressure inactivates the newly duplicated IGHE. Maintenance of multiple
functional IgG genes is common and it could be that the IGHE-IGHG cassette contains
sequences suited for unequal crossing over [200]. Regardless of the mechanism, two
IGHEs remain functional in ERBs. The more likely explanation for retaining two functional
IGHEs, as opposed to other mammals, is the diversification of the IgE functional response.
Gene duplications are not uncommon in the IGH locus, and occurred when IgY
underwent a duplication ~220-300 million years ago gave rise to two distinct Ig isotypes,
IgG and IgE, each performing a part of the functionality of the ancestral IgY. Additionally,
isotype duplications result in variable subclass number which have been documented in
several mammals. Thus, it is possible that a duplication of the IGHEs in ERBs could allow
for such a diversification in which each copy performs a specialized function(s) that was
previously fulfilled by a single IgE. An alternative but not mutually exclusive hypothesis is
that the expansion and diversification of IGHEs results in tissue specific expression. We
tried to discern between these two hypotheses by evaluating IGHE1 and IGHE2 tissue
expression, by comparison of the primary sequence of the two functional ERB IgEs along
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the mouse and human IgE, and by performing a structure-based multiple-level protein
function predictions (using COFACTOR and GO terms). IGHE2 is the only IgE gene
expressed in lung and bone marrow, while both IGHE1 and IGHE2 transcripts are
detected in the periphery (blood) and secondary lymphoid organs (LN and spleen) (Figure
11). The tissue expression pattern of both IgE genes leads us to hypothesize that IGHE2
could have diversified to perform an important role in the lung microenvironment, either
complementing or augmenting IgA function, and/or act as a sensing antibody to modulate
the IgG response in the lungs as is seen with many virus infections [201]. This notion was
further reinforced by GO term analysis, which revealed that ERB IgE subclasses vary in
predicted function (Figure 11). These include significant differences in prediction of the
phagocytosis function. While IGHE1 appears to mimic most of the other IgE species
described to date, the function is missing in IGHE2. Conversely, unique GO terms, e.g
“response to other organism”, are associated with IGHE2 but not indicated by IGHE1.
Moreover, a residue known to be important for CD23 (FcεRII) binding, glu414 [202], is
present in IGHE2 but not IGHE1 which may suggest less effective or ablated binding
capacity, further supporting a diversification of IgE function in ERBs.
In humans and mice, IgE class switching typically requires antigen, the presence
of cytokines (IL4 and IL13), and the CD40-CD40 ligand T cell interaction [203]. However,
another form of IgE, known as natural IgE, is produced without the need for antigen
presentation or T cell co-stimulation [201]. In humans, natural IgE does not undergo
somatic hypermutation and is directed against self-antigens, environmental toxins, and
parasites. Natural IgE’s specificity is dictated by the discrete combinatorial diversity in the
V(D)J repertoire. Due to the expansion of pan-viral IGHV genes it is possible that ERBs
natural IgE is capable of recognizing a broad range of pathogens without requiring costimulation, allowing for an innate-like adaptive response in which IgE rapidly detects a
wide breadth of viral antigens [204]. Further support for IgE sensing of viral epitopes is
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derived from the historical toxin hypothesis in which IgE acts as a sensor for detecting
miniscule amounts of a particular protein; acting as a surveillance mechanism for the
immune system [201]. Others have suggested that this could in turn enhance other
antibody responses, such as IgG, stimulating a complex and effective adaptive response.
Together, our data highlights the unique features of the ERB immune system and supports
a diversification in IgE function. IgE1 resembling the function in other mammals IgE
functions while IgE2 may have evolved a different function in the lung tissue, where it is
primarily expressed.
ERB contains four IgG subclasses, identical to the number of IgGs found in human
and mouse. Despite human and mouse containing the same number of functional IgGs,
they are not functionally equivalent [137]. Thus, we do not anticipate that the ERB IgGs
will share direct functional equivalence with any individual mouse/human IgG.
Transcriptomic data suggests ERB IgG1 is the highest expressed subclass (Figure 11),
especially in the periphery, lymphoid tissues and lung. ERB IgG4 is also principally
expressed in periphery and spleen, but also in lymph nodes, bone marrow and lung. ERB
IgG2 expression appears to be largely restricted to spleen, while IgG3 is very lowly
expressed, which is congruent with our inability to detect IgG3 via proteomic analysis.
Structure-based protein function predictions assigns each of the subclasses a distinct
specialized function that could not be directly correlated with either a human or mouse IgG
subclass. However, this prediction should be carefully interpreted after acquisition of
functional data. For example, while ERB IgG2 and IgG3 are 99.8% identical at the amino
acid level, differing by only one amino acid at the CH2 domain (IgG2: Thr182, IgG3: Ala182),
their GO terms predicted differences are significant (Figure 12). The predicted functional
differences are likely explained by this single amino acid substitution (Thr182Ala).
There are other structural features of interest in ERB IgGs. ERB IgG1 contains the
longest hinge and a single CPRCP domain which is also present, although expanded, in
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human IgG3. The long hinge of human IgG3 provides more flexibility to the two Fabs, but
also reduces the half-life of the immunoglobulin due to increased susceptibility to protease
degradation. Moreover, ERB IgG1 has a putative N-glycosylation site at the hinge
(PVKYTCDRENGSCSCCSACPRCP), not observed in any of the other ERB nor the
human IgG subclasses.
Another structural feature of ERB IgGs is the lack of the CXXC hinge domain in
ERB IgG2, IgG3, and IgG4. ERB IgG4 contains a --RC in that region, while ERB IgG2 and
IgG3 contain a –RS (Figure 10). This region of the hinge was associated with the ability
of human IgGs to form disulfide bonds between both IGHs chains. Human IgG4,
containing a CPSC domain in that region, was shown to undergo Fab-arm exchange and
can exist as “half molecules”, where the IGH:IGL dimer is associated by non-covalent
interaction with the other IGH:IGL dimmer [205]. Because of this human IgG4 does not
crosslink antigen and demonstrates bispecificity, most likely due to interchange of “half
molecules” between different IgG4 [206]. The fact that ERB IgG2, IgG3 and IgG4 lack the
hinge CXXC domain suggests three out of the four ERB IgGs might lack inter-chain
disulfide bonds between IGHs, and potentially form bispecific half molecules, similar to
human IgG4. However, it is important to note that all ERB IgGs have at least one cysteine
at the hinge in a conserved domain: “PV(K/E)YTCDR(E/G)”. For ERB IgG2 and IgG3, this
is the only cysteine, and its role in inter- or intra-disulfide bonds would need to be
elucidated. This hypothesis, if confirmed experimentally, might have a great impact in how
ERB humoral immunity works and affects their interaction with FcRs and complement.
Human IgG4 contributes to anti-inflammatory properties, limiting its ability to form
immunocomplexes and activate complement. If this is the case for all the ERB IgGs,
except IgG1, another mechanism of anti-inflammation might be present in this animal
species to control infection with low inflammation.
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Fc functions vary between subclasses while FcRs have conserved motifs
Considering the lack of antibody-mediated neutralization observed in vitro [133],
we decided to evaluate the key counterparts to Igs, the FcRs and humoral proteins that
bind and enable different antibody-mediated biological functions. ERB FcRs resemble
those found in mice, lacking the expansion observed in primates and specifically in
humans [143], [145]. Consequently, while the inhibitory receptor FcγRIIB is well
conserved, ERBs do not contain the expanded human activation FcRs (FcγRIIA and
FCγIIC) with Immunoreceptor Tyrosine-based Activation Motif (ITAM) at their cytosolic tail.
Therefore, ERBs FcRs can only transduce and activator signal through the accessory
signaling molecules (γ and β chains). ERBs also lack the GPI linked FcγRIIIB highly
expressed in human neutrophils [207]. Moreover, the high affinity FcγRI expressed in
ERBs has a particular feature in its trans-membrane sequence (Figure 13): While human,
cynomolgus, and rhesus macaques as well as mouse FcγRI have a conserved TM motif
with an Asn306 (in human: LAVGIMFLVNTVL), ERB FcγRI TM motifs contains an aspartic
acid in that position (LMVVTMFLVDTVF) which resembles the human FcγRIIIA (Figure
13) and FcεRI motif. This asparagine amino acid is crucial for association with the
signaling γ chain and also renders FcR membrane expression independent of γ chain
expression [208]. While Asp306 allows for interaction with the signaling γ chain, results in
receptor membrane expression dependent on γ chain expression [209].
In humans, NHPs, and mice, FcγRI is the high affinity IgG receptor [210]. The D2
domain FG-loop of FcγR in human FcγRI (171MGKHRY176) is one amino acid shorter
than the low affinity FcγRII and FcγRIII equivalent regions. An insertion of a valine in this
structure (e.g. FcγRIII: 171MVGKHRY177) is sufficient to decrease 15 fold the FcγRI
affinity for IgG [173]. A statistical analysis of this loop in different species showed that the
length of the high affinity FcγR is six amino acids and that additional amino acids
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drastically decreases affinity. Strikingly, ERB FcγRI has eight amino acids at the D2
domain FG-loop (171VGTSRRTF178) instead of the six observed in human, NHP and
mouse FcγRI (Figure 13). Moreover, although ERB IgGs conserve the N-glycosylation site
at Asn297; ERB IgG2, IgG3 and IgG4 had mutated one of the three critical binding contacts
with FcγRI. While all the ERB IgGs retained the CHγ2 FG loop Asp265 and the CHγ2 FG
loop, the lower hinge region (Leu233Leu234Gly235Gly236) is only conserved in ERB
IgG1, but not in the other subclasses. IgG2, IgG3 and IgG4 have the second leucine of
this motif substituted by a proline (Leu233Pro234Gly235Gly236). The mutation of the Leu234 is
associated with the inability of the IgG to bind FcγRs [174]. Even though the mutation of
the second leucine in ERBs was not functionally tested, based on data from mice and
human, this modification is expected to have a direct impact on the ability of these three
ERB IgG subclasses to interact with the FcγRI. This Leu234Pro substitution, together with
the ERB FcγRI D2 domain FG-loop structure, strongly suggests that the FcγR affinity for
the different ERB IgGs will be impacted. The threshold of interaction/activation of the
ERBs IgGs/FcγRs are predicted to be lower than the human and mouse orthologues and
is of high interest for further study. Since FcγRI has been implicated in inflammation in
human and mouse [211, 212] the distinct features observed in ERB FcγRI might imply
inflammation regulated by this receptor requires a higher threshold of activation.
Summary
Overall, we have identified a suite of features specific to ERBs that may aid in their
ability to overcome infection, reduce inflammation, and remain largely asymptomatic. In
this study we comprehensively characterized the ERB IGH locus including 66 IGHV
genes, 8 IGHD genes, 9 IGHJ genes, five IgE genes (two functional and three pseudo),
four IgG genes (all functional), one IgM gene (functional), and one IgA gene (functional).
We identified differential tissue expression of ERB Igs, potential functional differences,
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and alterations in effector mediating proteins, suggesting that the functional IgE genes
might be performing distinct function in different tissues. We identified features at the hinge
domain of IgGs that might affect the inter-chain disulfide bonds, generating “half
molecules” similar to human IgG4. We also identified the lack of the FcγR expansion
observed in primates and features of FcγRI that suggest a dependency on the γ chain for
expression and a longer FG-loop that would decrease the affinity for IgGs. Moreover, we
found that ERBs lack functional short pentraxins in clear contrast with humans and mice.
All of these findings support previous claims that ERB is biased to tolerance to viral
infection with reduced inflammation.
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Chapter 3:

Mechanisms of diversity in the V(D)J repertoire of Egyptian rousette

bats

Introduction
The immune system’s ability to respond with high-affinity antibodies to a wide
assortment of antigens is hinged on the generation of a diverse B cell repertoire dictated
by the IGH germline and further antigen-driven selection and affinity maturation. The ability
to recombine genes to create a great number of diverse binding units able to recognize
different epitopes and elicit a potentially protective response to pathogens is paramount
to adaptive humoral protection. Assembly of B cell receptors (BCRs) is achieved through
recombination of germline-encoded gene segments: variable heavy (VH), diversity heavy
(DH), joining heavy (JH) and constant heavy (CH) for the Ig heavy chains and variable
light (VL) and joining light (JL) for Ig light chains. Our approach focused only on the heavy
chain recombination as IGH IgSeq is enough to define and characterize the BCR
repertoire and study the mechanisms of V(D)J recombination [213-217]. The portion of the
antibody encoded by V(D)J is part of the Fab domain and is responsible for antigen
binding. We were also interested in determining the mechanism(s) of B cell diversity which
requires comparing BCR repertoire sequencing (IgSeq) data to reference genes (IGH
germline).
Three mechanisms are used to varying degrees in different species to generate
antibody diversity: 1) combinational diversity (CD), 2) somatic hypermutation (SHM), and
3) somatic gene conversion (SGC) [218]. Potential combinations of V(D)J for the heavy
chain and VJ for the light chain define CD through recombination. SHM is the process in
which single nucleotide polymorphisms are introduced and alter antibody specificity
through affinity maturation while SGC is the process in which portions of the VH gene are
homologously recombined with upstream VH regions to modify receptors. Both SGC and
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SHM affect the complementarity determining regions (CDR) of the Fab domain which
binds antigen. While they can occur across both framework regions (FWR) and CDRs,
mutations are best tolerated in CDRs as FWR confer important structural features. In
particular, the CDR3 region is considered integral to specificity as it has the additional
diversity garnered by the imprecise combination of V(D)J which includes additions
between VD and DJ recombinations (Figure 16).
Co-evolution with pathogens plays a critical role in shaping antibody repertoire
diversity and specificity. At the germline, positive selection on germline-encoded VH
segments is thought to result in preservation of VH segments utilized in protection against
commonly encountered pathogens over a long period of host-pathogen evolutionary
history [219]. Bats are natural reservoirs for a variety of RNA viruses and account for a
majority of emerging diseases [220]. Despite having active viral infections, bats rarely
display clinical symptoms [221]. Negative strand RNA viruses MARV, RAVV, and SOSV
present asymptomatically in ERBs [222] but cause a severe disease in primates that can
be up to 90% lethal for MARV [132]. ERBs have been shown to produce a protective
antibody response when exposed to the MARV, RAVV, and SOSV [21, 132], however,
nothing is known about BCR generation in ERBs or their diversification mechanisms. To
this end, I developed a molecular and bioinformatics protocol to recover, sequence, and
analyze BCRs from ERB IgM (to represent naïve B cells) and IgG (to represent antigen
experienced B cells more prone to SHM or SGC) (Figure 15). Here, I report the first
molecular characterization of BCRs from ERBs.
In this study, we present evidence based on the genes identified in RaegypIGH3.0
that the potential CD of the V(D)J genes in ERBs is about half of what is possible in the
human genome (Larson et al 2020, submitted). We also found ERBs IgM had elevated
SHM when compared with human IgM. Interestingly, ERB and human IgG SHM rates were
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not significantly different suggesting that the higher SHM in IgM is not due to missing
germline genes or alleles as a reference. In Yangochiroptera, transcriptionally based
studies indicated potentially 236 VH3 genes alone in the germline [223]. When calculating
SHM, the authors were not able to distinguish between no SHM or so high SHM that the
genes were indistinguishable from the described germline genes as they did not have a
complete IGH locus to compare back to. They report some of these may be alleles, as
was seen when mice were originally estimated to have more than 1000 VH genes which
is now known to be a significant over estimate (BALB/c has only 101 functional VH genes)
[223]. Based on our findings, it is possible that the transcripts from this order of bats also
displays higher SHM and could account for the over estimation of germline genes. To
confirm this hypothesis, a contiguous IGH locus for Myotis lucifugus would be required.
The data presented here fits with what is currently known for other Yinpterochiroptera bats.
The average number of IGHV genes described within this family of bats is ~60 genes,
which we also report for ERBs and additionally placed them all on one locus. My research
advanced the field as I describe the mechanism of BCR diversification which is a first in
any Yinpterochiroptera species in addition to defining V(D)J combinations of another
pteropid species [139]. This represents the first comprehensive analysis of any bat species
BCR repertoire in that we describe potential CD and identify the likely mechanism of
additional diversity. These data support unique features of adaptive humoral immunity in
ERBs and could in part explain the ability of this species to overcome lethal pathogenic
human viruses which could ultimately aid in the development of novel therapeutics.
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Figure 15: Illustration typical V(D)J repertoire protocol.

PBMCs are isolated from whole blood, then RNA purified from cells. RNA is converted to
cDNA using a 5’RACE protocol at manufactures specifications. An immunoglobulinspecific PCR is done to amplify isotypes of interest. Products are prepared as libraries for
the Illumina Miseq platform, sequence, and sequences analyzed using a combination of
R, Python, and Perl scripts.
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Figure 16 : Framework regions and complementarity determining region map.
The V(D)J region can be further described by framework regions 1-4 (FWR1-4) and
complementarity determining regions 1-3 (CDR1-3) that play structural or binding roles,
respectively. CDR3 includes gap regions (red) from the imprecise process of
recombination that adds diversity in these junctional sites.
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Methods
Animals
RNA was isolated from PBMCs from four healthy ERBs maintained at the CDC.
Research was conducted under an IACUC approved protocol and complied with the
Animal Welfare Act, PHS Policy, and other Federal regulations and statues relating to
animal experiments. The work was conducted at an accredited facility by the Association
for Assessment and Accreditation of Laboratory Animal Care, International and adhered
to the principles in the Guide for the Care and Use of Laboratory Animals, National
Research Council, 2011.
Generation of RNA transcripts from ERB
RNA from ERBs was provided from Jon Towner at the CDC. RNA was isolated
from 2x10^6 PBMCs from individual bats using RNAzol and ethanol. Quality was assessed
with RNA tapestation. cDNA was generated using 5’RACE and superscript II under
standard kit conditions. cDNA was cleaned up with 0.7x volume AMpure beads and
underwent target enrichment PCR with primers specific to the 5’RACE and either the IgM
or IgG constant exon 1. Samples were then library prepped on the Apollo system at 520bp.
Samples were collected and cloned using a TOPO II blunt vector. Colonies that grew on
Kanamycin plates were grown again overnight at 37°C shaking and gDNA was isolated.
Insert size was confirmed via EcoR1 digest on a 2% gel. Products with appropriate size
were sent for Sanger sequencing. Once libraries were confirmed to have rescued the
amplicons of interest using IMGT HighVQuest and manual annotation methods, libraries
were sequenced on the Illumina MiSeq using a 600 cycle kit (2x301 cycles) following
Illumina protocols. Samples were pooled and diluted to 2nM after qPCR and denatured
with 0.1N NaOH along with 30% 2nM Phix spike-in. Paired reads were merged with
FLASH and used to validate gene annotation. Sequences were submitted to IMGT for
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annotation, then re-annotated post germline definition and collapsed by UMI and 98%
CDR3 for transcriptional analysis [224].
Identification of IGHV, IGHD and IGHJ genes
IgM sequences were filtered to remove reads that lacked both the constant primer
and a 5’RACE, All VDJ transcripts passing filters were submitted to IMGT HighVQuest for
annotation [225]. Gene nucleotide sequences were extracted and mapped against the
BCR back to confirm functionality of annotated genes and identify likely locations of IGHD
and IGHJ genes. If a transcript mapped to the BAC using the map to reference feature of
Geneious, the region was manually inspected for recombination signal sequences, open
reading frame, and conserved motifs. If all were found, the gene was annotated manually
based on which transcripts were mapping to that gene. If multiple transcripts with different
annotations mapped to one gene, the more prevalent annotation was kept and confirmed
via phylogeny with other ERB and human genes.
Somatic hypermutation calculation
As most current somatic hypermutation analysis programs utilize human motifs in
the determination of mutation rate, a novel method of analysis was required. The percent
of SHM across ERB VH genes was quantified using an original bioinformatics pipeline
implemented using BioPython, R, and the NCBI BLAST command line module. To recover
V gene sequences, IgM transcripts from ERBs were sequenced and annotated using
IMGT [225]. Annotated VH gene sequences were then aligned to the germline Ig genes
using the BLAST algorithm. Both the number of nucleotide differences per transcript VH
gene and the location of these differences were cataloged by SHMscript.py. The overall
mutation percentage per VH family as well as across CDR and frame work regions (FWR)
were visualized using R packages. Diversity metrics were assessed using IMGT output
and VDJtools pipeline [224].
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Figure 17 : SHM calculations schematic
V(D)J reads were aligned to a set of reference genes from RaegyptBCR3.0. Individual
bins were maintained for each VH family and then the number of changes relative to the
reference gene counted and averaged. Sequences that could not be placed with one of
the references were discarded, and accounted for less than 1% of total reads.
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Results
Combinatorial diversity potential and usage in ERBs
The antigen binding capacity of an antibody is initially set by the recombination of
a V(D)J for the heavy chain and V(J) for the light chain. Initial diversity can be assessed
by comparing the unique number of combinations a germline repertoire could form. To this
end we focused on determining the composition of both genes in the new assembly for
the IGH, RaegyptBCR3.0, and the previous assembly for IGL, Reagypt2.0. We recently
generated one contiguous IGH locus for ERBs and meticulously annotated 66 VH, 8 DH,
and 9 JH genes (Larson et al 2020, submitted). Based on these results, the IGH V(D)J CD
capacity in ERBs is 4,032 (56x8x9) as ten VH genes are pseudo genes and would not
produce functional BCRs. In humans, there are ~50 functional VH genes, approximately
27 DH genes, and six JH genes which could create ~12,150 unique combinations [226].
Suggesting that the base CD in ERBs is nearly a third of what is possible for humans.
However- without proper annotation of the Ig light [227] chains VL and JL genes, the actual
CD cannot be ascertained. The IGL loci are also highly repetitive and difficult to assemble,
with the additional hurdle of being spread across not one locus but multiple loci. In humans
these genes fall into two chains on two separate loci, kappa (IGLK) and Lambda (IGLL)
[228]. Although the IGL loci remain uncharacterized, Raegypt2.0 has 158 IGLLV and 2
IGLKV genes. As humans have 71 IGLLV and 76 IGLKV genes, the diversity by
combination then becomes 645,230 for ERBs and ~3.5x106 for human- a substantial
difference [218].
The relationships between the IGL isotypes across evolutionary time are less well
understood than for IGH isotypes [229]. Raegypt2.0 has 29 putative IGLL constant genes
(IGLLC) and no IGLK constant genes (IGLKC). IGLKC is missing in birds and potential
Yangochiroptera, so to further confirm or refute its absence, IGLKC was ultimately
identified by BLAST using anther Yinpterochiroptera species IGLK (Pteropus vampyrus,
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LOC105302304). We identified NW_01549288.1 (74240-74748) as the ERB IGLKC gene
with 92% identity and 84% query cover, with 67% identity to the human ortholog of IGLKC.
Despite a large potential IGLLC repertoire, IGLLC7 was the most common in
transcriptomic data as well as proteomics (data not shown) [154]. However, these loci face
the same issues as the IGH locus and reports based on published scaffolds alone could
lead to artificially high counts. To this end, ERBs will be examined further to define the
light loci and functional repertoire in another study.
Usage of V(D)J genes in ERBs
We wanted to assess the actual CD of IGH genes in ERBs so we developed a
method to be able to sequence Ig transcripts containing IGH V(D)J sequences. The BCR
repertoire sequencing was successfully applied to other mammals to recover of V(D)J
transcripts [214, 230, 231]. We adapted this method, but specifically targeted ERB Igs
(IgM and IgG). The rational to focus on the BCRs of ERBs’ IgM and IgG was to compare
a more naïve subset (IgM, closest to the germline) to an antigen-experienced subset (IgG,
produced after one or more rounds of class switching). Since few reagents exist for ERBs,
this approach allowed us to lay the groundwork for future studies and comprehensively
describe the B cell repertoire in ERBs. As ERB germline sequences are not currently in
the IMGT database, we further conformed our data to the recent annotation of ERB
germline V(D)J genes (Larson et al 2020, submitted). The most prevalent IGHV family
used in V(D)J rearrangement was VH3, with approximately three genes contributing more
than 10% of the V(D)J rearrangement in each for each individual bat (Figure 18). The next
most predominate family was VH1, then VH4, and finally the single member family VH7
(Figure 18A). Variation between individuals was observed as was anticipated, but overall
trends for family dominance were preserved as is seen in humans [217]. As each studied
species appears to have a different composition of VH families as well as predominate VH
family usage, these features are key in dissecting differences in response (Table 9). We
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found that V(D)J rearrangements containing VH3 were predominate in ERBs, which is
common in mammals but the extent to which the dominant family contributes varies
between species which contributes to unique repertoires. (Table 9). Even though
differences between individuals are observed, the overall expression allowed me to
evaluate the most commonly expressed DH genes (Figure 18B). Based on the finding that
ERBs have an expansion of JH4 genes, we wanted to determine if these genes were
expressed differently. We observed preferential usage of four of the five JH4 genes in
ERBs, suggestive of a strong selection of this gene family, with JH4.5 responsible for
highest expression between subjects and isotypes (Figure 18C). While majority of
transcripts were found to contain a JH4 gene similar to what is observed in humans, the
usage differed between these highly similar genes varied greatly. In fact, one of these
expansions, IGHJ4.1, contributes little to the repertoire, despite only varying by a few
nucleotides (Figure 18C). Interestingly, the least used JH4 gene has two mutations in the
FWR4 region, one of which changes the codon (V17I) (Figure 19). The second least used
JH gene, JH4.2, also has a mutation in the FWR4 region (V15L). These mutations do not
compromise the predicted open reading frame, but may confer a disadvantage to the fully
assembled antibody which leads to decreased overall usage in JH4.1 and JH4.2. Multiple
JH4 genes have not been reported in any other species, and overall the combinatorial
diversity is significantly less than what is reported for Yangochioptera. This data supports
the large differences in these species and that features prevalent in Yangochioptera may
not be prevalent in Yinpterochiroptera [139].
We found that all but one functional VH gene was used (VH6), all eight DH genes,
and seven of nine JH genes- however usage varied between individuals as was
anticipated. Our recent work on RaegypIGH3.0 indicated impaired heptamers for the two
JH genes not seen, supporting their lack of expression. This decrease in usable segments
makes the actual CD closer to ~3,472 which is almost a third to the CD in humans.
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Figure 18 : V(D)J gene usage across four ERBs for IgM and IgG.
V(D)J sequences were annotated using IMGT High-VQuest then reannotated with an in
house script to follow with the new annotations from RaegyptBCR3.0 not yet in the
database. For four ERBs IgM and IgG are shown for A) IGHV, B) IGHD, and C) IGHJ.
*Unpublished. Preparing for Journal of Immunology.
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Figure 19 : IGHJ gene alignment of WGXG motif.
Alignment in Geneious of germline IGHJ genes from ERBs. The framework region in JH
genes begins with a structurally conserved WGXG motif present in all functional JH genes.
Variation is observed in the 5’ end that falls within CDR3 and the least used JH4 gene,
JH4.1, has a mutation that changes the conserved 3’ valine.

*Unpublished. Preparing for Journal of Immunology.
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Table 9 : VH families between species
Species
B. taurus

Functional VH
Families (#)
1

VH Families
Transcribed
VH1

S. scrofa
C. familiaris
E. caballus
R. aegyptiacus
P. alecto
M. lucifugus
H. sapien
M. mulatta
C. porcellus
M. musculus

1
3
3
4
5
5
7
7
3
14

VH1
VH1, VH3, VH4
VH1- VH3
VH1, VH3, VH4, VH7
VH1-VH5
VH1- VH5
VH1-VH7
VH1-VH7
VH1- VH3
VH1-VH14

Highest
transcribed
VH1
VH1
VH3
VH1
VH3
VH1
VH3
VH3
VH3
VH3
VH1
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A

B

Figure 20 : Representative V-J usage chord diagram and Heatmap.
A) Chord diagram illustrates which V genes pair with which J genes in repertoire. B)
Heatmap of individual VH genes pairing with individual JH genes. The most common
combination is that of V3-74 and J4.2.

*Unpublished. Preparing for Journal of Immunology.
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CDR3 composition in ERB repertoire
As the CDR3 is known to play a critical role in antigen binding, so much so that the
exact same antibody with only changes to CDR3 recognize different antigens [232]. We
sought to characterize common features of this region of ERB antibodies as it was
previously uncharacterized. The mean length of IgM CDR3s was 48.5+/-2.6 nt while the
mean length of IgG CDR3s was 45.4+/12.8 nt, similar to the mean sizes observed in
humans [196]. The CDR3s were high in aromatic residues like tyrosine and tryptophan
which are indicative of broad binding capacity (Figure 21). This capacity could be
beneficial for antigen recognition but would also pose risk for autoimmunity from selfreactivity [233]. Overall, the most abundant amino acids used in ERB IgM CDR3s were
tyrosine (Y, 12.33%), glycine (G, 10.96%), and tryptophan (W, 10.59%) while IgG CDR3s
were highest in tyrosine (Y, 12.85%), tryptophan (W 9.51%), and alanine (A 9.17%).
Overall there was not a significant difference between ERB CDR3 amino acid composition
between IgM (representing a more naïve B cell population) and IgG (representing antigen
experienced B cells) (Table 10).
An important facet of CDR3 composition comes from the junctional diversity
regions between VD (Gap 1) and DJ (Gap 2) (Table 11). The imprecise mechanism of
recombination allows for greater diversity and is primarily mediated by Palindromic (P)
and Non-templated (N) additions. Based on IMGT annotations, we found ERB IgM Gap 1
and Gap 2 to be 8.70 nt and 9.40 nt while ERB IgG Gap 1 and Gap 2 were 7.99 nt and
10.21 nt, respectively (Table 11). While the average gap length is similar to humans, the
range appears to be larger for ERBs in both IgM and IgG which could offer additional
diversity in the potential BCR repertoire of ERBs.
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Figure 21 : CDR3 amino acid composition of ERB IgM and IgG
IMGT annotated CDR3 regions were examined for amino acid combination between IgG
and IgM of ERBs. Average of four ERBs shown with standard deviation error bars.
*Unpublished. Preparing for Journal of Immunology.
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Table 10 : Amino acid composition of CDR3s in ERBs
AA
A
R
N
D
B
C
Q
E
Z
G
H
I
L
K
M
F
P
S
T
W
Y
V

IgM
7.27%
5.26%
2.20%
5.43%
0.00%
7.46%
0.73%
5.06%
0.00%
10.96%
1.75%
2.10%
2.26%
1.53%
1.04%
6.09%
1.53%
8.04%
4.90%
10.59%
12.33%
3.47%

IgG
9.17%
5.74%
3.10%
7.20%
0.00%
7.59%
0.56%
5.73%
0.00%
8.87%
1.15%
2.26%
2.45%
1.63%
0.95%
5.24%
1.93%
6.61%
4.14%
9.51%
12.85%
3.32%
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Table 11 : Gap lengths of CDR3 from ERBs.

Gap 1
Gap 2

IgM
8.7+/-1.56
9.4+/-1.53

IgG
7.99+/-2.45
10.21+/-1.51
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Somatic hypermutation in ERBs
Although some have speculated the major BCR diversity mechanism in
Yangochiroptera is either extraordinarily high SHM or SGC, it remained undetermined for
any bat species [223]. To verify or refute the hypothesis that this could be a general trait
for Chiroptera, we studied the BCR diversity mechanisms in ERBs. We compared
repertoire VH genes to germline VH genes annotated from Raegypt3.0BCR for single
nucleotide changes (SHM) as well as stretches of changes indicative of homologous
recombination with upstream VH genes (SGC). Our analysis supports SHM as the major
diversity mechanism for ERBs, similar to other mammalian species. These alignments and
subsequent calculations followed the expected mammalian pattern of higher mutations in
CDRs than FWRs (Figure 22). Overall, IgM VH genes varied by 5.21+/- 2.08% to reference
genes whereas IgG VH genes varied 11.13+/-1.17% to reference genes. In humans, IgM
variation between transcripts and genomic genes is ~3% while IgG is around ~8% [234].
To verify our methods, we repeated this process on IgM and IgG from human and found
2.59+/-1.37% and 10.87+/- 3.54% (data not shown). A student T-test confirmed variation
in VH genes of the repertoire to VH reference genes of IgM was significantly elevated in
ERBs at a p < 0.001 (Figure 23).

96

Percent Difference

IGHV1

10.0

Region of VH Gene

7.5

5.0

2.5

0.0
FWR1 CDR1 FWR2 CDR2 FWR3

Percent Difference

IGHV3

10.0

7.5

5.0

2.5

0.0
FWR1 CDR1 FWR2 CDR2 FWR3

Percent Difference

IGHV4

10.0

7.5

5.0

2.5

0.0
FWR1 CDR1 FWR2 CDR2 FWR3

Percent Difference

IGHV7

10.0

7.5

5.0

2.5

0.0
FWR1 CDR1 FWR2 CDR2 FWR3

Figure 22 : CDR3 mutations across VH families.
Location of mutations identified by SHM script in FWRs and CDRs of ERB IgSeq for each
VH family.
*Unpublished. Preparing for Journal of Immunology.
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Figure 23 : Percent difference from transcripts to reference VH genes in ERBs
(RA) and humans (HS).
Percent difference relative to reference genes for IgM (top) and IgG (bottom).
Significance tested by student T-test.
*Unpublished. Preparing for Journal of Immunology.
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Discussion
Lower combinatorial diversity in ERBs than humans
The ability for ERBs to overcome MARV, RAVV, and SOSV infections without
symptoms may rely in part on a protective antibody response. A species’ antibody
repertoire is built upon the genes encoded in the germline and so the number of unique
combinations possible is a critical first determinant of overall diversity. The IGH locus of
ERBs contains 66 VH, 8 DH, and 9 JH genes (Larson et al 2020, submitted). This plus the
comparable IGL genes suggest a potential for less than a third of the combinations for
human V(D)Js. While the number, composition, and usage of these genes varies between
each studied species, particular genes have been linked with a protective response to
specific pathogens in different species [235]. The presence (and expansion) of these
“protective” genes in the IGH germline would be beneficial for the animal frequently
exposed to those potential pathogens. Moreover, a wider and more diverse B cell
repertoire would be favored, as it would increase the chances of having a beneficial BCR
within the B cell population [236]. Beyond the composition of these genes in the genome,
we wanted to know the usage and applied IgSeq to recover and examine V(D)J transcripts.
We found that majority of the functional genes were used between the individual animals
tested, similar to what is seen in other mammals [216].
CDR3 composition supports polyreactive antibodies
To examine if ERBs are capable of a more broad antigen binding that could
compensate for diminished CD, we characterized the amino acid composition of the CDR3
region. The CDR3 of antibodies is the junction between the IGHV, IGHD and IGHJ genes,
contains the VD and DJ gaps, and is regarded as the most important region for antigen
binding and recognition [236]. We found evidence that supports polyreactive antibodies
which have CDR3 regions high in aromatic residues like tyrosine and tryptophan. These
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residues interact with diverse antigens by forming a “sticky” antigen-binding site [237,
238]. The discrete differences in CDR3 composition between species may indicate a bat
species specific preference in CDR3 amino acid composition [139]. For example,
differences exist between germline VH segments (VH1, VH3, VH4, VH7 in ERB vs VH1,
VH2, VH3, VH4, VH5 in P.alecto) that skew amino acid preference and would imply
differences seen between ERB and other Yinpterochiroptera. This difference could also
be heavily influenced by antigen exposure- since the ERB examined come from colony at
the CDC kept in biocontainment while the P.alecto studied were wild-caught animals,
(which have an unknown history of viral exposure). Although broad antigen permissibility
is often a hallmark of autoimmune diseases, a decrease in arginines in the CDR3 may
counter-act the broad capacity of the binding pocket as arginine is correlated to
autoreactive antibodies in humans [236].
The imprecise recombination that results in P and N additions are mediated by
terminal deoxynucleotidy transferase (dTNT). P nucleotides occur because Artemis
cleavage is often asymmetrical, resulting in a short and long strand that requires
extension. N nucleotides are random additions of 2-20 bp. This leads to over 66% of JH
region rearrangements resulting in nonfunctional antibodies [239]. While we found that
ERB gaps were similar to humans on average, there was a wider range in gap length
which could afford more diversity in final rearrangements.
Evidence of higher somatic hypermutation in ERB IgM than humans
The BCR diversity mechanism in ERBs was unknown. We compared repertoire
VH genes to germline genes which supports SHM as the major diversity mechanism. The
finding that ERBs have elevated SHM in IgM could mean ERBs are capable of producing
more broadly reactive antibodies. It has been well documented that high levels of SHM
and long CDR3s are common for broadly neutralizing antibodies (bnAbs) [240, 241],
however, very low SHM has also been associated with bnAbs highlighting the gradient of
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possibilities in the antibody response [185]. Although it has been shown that ERBs don’t
generate neutralizing IgG antibodies to MARV [133], they may in fact be generating
neutralizing IgM, IgA or IgE antibodies which are important for mucosal exposure to
viruses like influenza [242]. Higher SHM could also support that ERB antibodies are able
to tune a response quickly without multiple rounds of affinity maturation [243]. Indeed,
cattle which have a propensity to generate rapid broadly neutralizing antibodies are known
to have longer CDR3s and different patterns of SHM [244]. Although ERBs appear to have
less CD than humans, they may compensate for limited CD diversity through other
diversity mechanisms as is suggested in chickens, which also have diminished capacity
for CD relative to human [236]. It is possible that IgM plays a larger role in the ERB
response to pathogens, and thus the higher SHM allows for a wider breadth of response
than what is seen in humans. This mechanism may allow for a rapid, pan-pathogen
response that protects ERBs from overt symptomology sooner than waiting for class
switching to IgG.
Summary
Bats represent a diverse and species-rich group of mammals that have evolved
distinct characteristics since their divergence from other mammals. Despite the role they
play in viral spillover to other species and the apparent lack of overt symptoms to
pathogens that cause human pathology, little is known about their anti-viral response and
in particular their BCR repertoires. To identify genes involved in the BCR repertoire of
ERBs, we developed and demonstrated the first ERB IgSeq methodology from bench to
analysis. Understanding the immune response of ERBs to MARV and other pathogens
could aid in development of effective medical counter measures but was previously
hampered by lack of gene annotations, reagents, and protocols. We have defined the
base repertoire of ERB V(D)J’s as well as identified the likely mechanisms that contribute
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to receptor diversity. Interestingly, SHM varied between gene families with the largest
gene family being closest to the overall mutation rate, similar to what is seen in humans
while families like VH7 saw very little SHM. In conclusion, using high-throughput
sequencing of ERB BCRs we were able to describe the overall repertoire of this important
reservoir host. The identification of sticky amino acids in the CDR3s suggest a broadlybinding capacity of ERB BCRs not previously reported. This combined with the decreased
potential heavy CD leads us to suspect a broad-response although it is not improbable
that an expansive IGLV repertoire might rescue the CD overall. These data support the
hypothesis that ERBs may be protected from MARV and other viral infections by a broad
humoral response that elicits protection without overt inflammation seen in other
mammals. This may be in part due to the expansion of novel Ig isotypes described
previously, as well as the potential natural antibody repertoire. To our knowledge, this
study provides the first description of ERB BCR repertoire and the first evidence of a B
cell diversity mechanism in a Yinpterochiroptera species. This study lays the groundwork
for future studies to decipher the humoral response of ERBs to MARV, RAVV, and SOSV
and provides key insight into the generation of the antibody response by ERBs.
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Chapter 4:

Profile of Marburgvirus epitopes ERB antibodies recognize

Introduction
Monoclonal antibodies have proven successful as therapeutics in recent EBOV
outbreaks [52]. As a strong humoral response is linked to vaccine efficacy for filoviruses,
and convalescent serum from EBOV and MARV vaccinated NHPs provides protection by
passive transfer, discovery of novel protective antibodies is a bright course of pursuit [80].
While no FDA-approved treatment currently exists for MARV, many mAb treatments are
being used for EBOV [245]. However, recent findings suggest EBOV immunodominant
epitopes alone might not be adequate vaccine targets to control viral infection. This is also
observed in other viruses, such as influenza virus and HIV, in which the immunodominant
antigenic target reduces the efficacy of vaccination while other antigenic regions elicit
broad-spectrum neutralizing antibodies [128]. Recently, we assessed the polyclonal
response to EBOV at an epitope level using a technique known as Domain Programmable
Arrays (DPA), a phage display, high-throughput serological platform for epitope mapping
(Figure 24). This technique takes advantage of the classical phage display system, a
comprehensive detection array of synthetic oligos, and a bioinformatics metrology to
comprehensively identify domain variants within epitopes [128]. We further validated this
technique in another bat species, Schreiber’s Bent-Winged Insectivorous bats, for their
response to a lesser known filovirus, Lloviu virus (LLOV) [36].
To this end, applying this technique to the reservoir host of MARV might identify
unique regions of recognition that primate antibodies do not detect. If so, those epitopes
could offer significant protection and in theory be generated and given as therapeutics.
We have optimized the DPA technique for use with ERB sera and tested multiple naïve
and MARV challenged ERBs as well as naïve and MARV GP vaccinated NHPs. We found
that ERBs recognize a wider breadth of MARV GP, which crosses the GP1/GP2 cleavage
site and could potentially offer protection by controlling viral spread.
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Figure 24: Domain Programmable Array overview.
The DPA assay is set up similar to an ELISA in which sera is added to a 96-well plate and
incubated with phages displaying filovirus oligos that span the entire coding region. Bound
phages are subsequently recovered and sequenced and a bioinformatics pipeline used to
normalize the data.
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Methods
Animals
Serum was isolated from ERBs on day 56 post two sequential challenges with
MARV (days 0 and day 28) by our CDC collaborators. Research was conducted under an
IACUC approved protocol and complied with the Animal Welfare Act, PHS Policy, and
other Federal regulations and statues relating to animal experiments. The work was
conducted at an accredited facility by the Association for Assessment and Accreditation
of Laboratory Animal Care, International and adhered to the principles in the Guide for the
Care and Use of Laboratory Animals, National Research Council, 2011.
Domain programmable array screening
Protein-coding domain sequences from all filovirus strains deposited into GenBank
as of December 2016 (EBOV, SUDV, TAFV, BDBV, RESTV, MARV, RAVV, and LLOV)
were retrieved, and coding sequences split into 30 amino acid (aa) peptides that tiled
every seven aa (Figure 25). Identical sequences were eliminated and the remaining
12,735 codon-optimized peptides were synthesized on high-density microarrays, cloned
into a T7 phage display system, and deep-sequenced to confirm successful display. A 96well plate was blocked with 10%BSA in 0.1N NaHCO3 for two hours at room temperature.
Then sera was added at a 1:500 dilution in PBS in triplicate and incubated at 4°C
overnight. Wells were washed with TBST eight times and 100uL/well 2M urea was added
to recover phages. The recovered phages were lysed and cloned oligonucleotides
amplified via PCR (T7 forward primer: GGA GCT GTC GTA TTC CAG TC / T7 reverse
primer: CCC CTC AAG ACC CGT TTA GAG GCC C) using triplicate primers with a 5’
staggered end. The PCR protocol followed T7 Clontech specifications. Triplicates were
pooled and cleaned using Zymo-5 column clean up beads and 70% ethanol. Samples
were resuspended in 20uL Illumina buffer and size checked on the DNA tapestation.
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Figure 25 : Construction of the DPA phage oligo library.
All open reading frames were pulled from NCBI for current filoviruses. Sequences were
then chopped into 30 amino acid sequences tiling the ORFs by seven amino acids to
ensure full coverage.
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Sequencing
DNA was quantified by Nanodrop and 100 ng used for an Illumina 220bp library
preparation on the Apollo 324 (Wafergen) system using the Prep X kit (Wafergen complete
IIMN DNA library kit). Libraries were then enriched using the library amplification kit
(KAPA) and a post-enrichment clean-up done on the Apollo 324. Libraries were then
pooled to 2nM and sequenced on a MiSeq DNA sequencer instrument using a 600 cycle
kit (2x250) with 20% PhiX.
Bioinformatics
An in-house developed pipeline was developed previously that performs the
following: Array Description, Input Randomization, Removal of Duplicates and Read Mate
Correction, Read Cleaning, and Expression Analysis. The DPA analysis pipeline can be
downloaded at https://github.com/kygarcia/DPA_Analysis_Pipeline. The reporting module
creates an HTML and EXCEL based output that was reworked for this project to highlight
strain of interest (MARV) and fix minor display issues. Each library was run in triplicate
and T-tests and Chia Square performed to remove peptides that fail either if P > 0.05.
Western Blot to Confirm Immunodominant epitopes
Non-overlapping peptides were selected from DPA results and synthesized
including a glycine linker and biotin. Peptides were diluted to 1mg/mL water immediately
before use and stored at -20C.Peptides were used as antigen in the WES (Protein Simple)
system. Assay conditions were done following the manufacture guidelines (Protein
Simple). Biotinylated peptides were mixed with 5X Fluorescent Standard, DTT, and 1X
Sample Buffer (WES Reagents) for a final concentration of 0.8 μg of protein, and loaded
and run in the capillary system. Antigen was detected using the serum diluted at 1/100,
1/500 or 1/1000 in PBS, and further developed using the isotype specific secondary
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antibodies. Anti-rabbit HRP Antibody and the provided peroxidase and Luminol-S reagent
were used to develop the assay. Results were analyzed using the Protein Simple software
Compass. Western-blots were not performed quantitatively, and instead scored only as
“positive” or “negative.” An anti-biotin HRP antibody (CAT) was used as a positive control
for peptide sizing, and negative controls included a well without antigen, a well without
primary, and a well without secondary.
Results
Profile of all MARV Epitopes ERB Antibodies Recognize
Four ERBs that were challenged with MARV on day 0 and day 28, and five ERBs
that were mock challenged with media alone were all bled on day 56. Serum was bound
to polysterne plates and then the phage library added and incubated. After multiple
washes the bound fraction was recovered and sequenced. We found that the antigen
recognition breadth was increased in ERBs after one challenge of MARV and even more
so after a second dose of MARV (Figure 26). We noted that this individual ERB’s
recognition crossed the GP1/GP2 cleavage site so we repeated with different animals to
confirm. We found that there was a conserved public response recognizing much of MARV
GP which indeed did cross the GP1/GP2 cleavage site (Figure 27). We detected
recognition at the GP1/GP2 cleavage site consistently in ERBs. However, we did not find
clusters in all four ERBs despite repeating the experiment and altering conditions. This
could be due to a lack of seroconversion in this subject, so to confirm exposure we
conducted an ELISA. We found that all challenged ERBs had positive titers while all
control animals had negative titers (Figure 28). Unfortunately, this was the last of this
experimental sample and could not be explored further.
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Figure 26 : ERB response to MARV after a single, or double challenge.
Three sera samples were received from the CDC. One which had not been challenged,
one that had been challenged once, and one that had been challenged twice [246]. All
were analyzed for their recognition of MARV (bottom). Bars represent span of oligo
recognition.

*Unpublished. Preparing for Viruses.
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Figure 27 : ERB responses to MARV after a double challenge.
Nine sera samples were received from the CDC. Five that had not been challenged and
four that had been challenged twice [246]. All were analyzed for their recognition of MARV
(bottom). Bars represent span of oligo recognition.

*Unpublished. Preparing for Viruses.
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Figure 28 : ELISA titer for ERBs
Nine ERBs, four challenged with MARV on day 0 and day 28 and five challenged with
media were examined for recognition of GP day 56 post first challenge. IgG antibodies
were detected by ELISA using a purified recombinant Glycoprotein of the Angola Strain
of Marburg virus. Antibody levels expressed as adjusted sum OD values while dotted
line represented the threshold of the assay. MARV seropositive >0.15.
*Unpublished. Preparing for Viruses.
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Profile of all MARV Epitopes NHP Antibodies Recognize

We repeated the procedure with serum from seven NHPs, six that were vaccinated
with MARV-GP twice and one that was mock challenged with the vehicle alone. We found
that three of the six vaccinated animals mounted detectable epitope recognition via DPA
(Figure 29). Further, one of the animals that mounted a response perished. We found no
recognition of the GP1/GP2 cleavage site in NHPs and few overlaps in response. These
results make comparisons to ERBs difficult as the vaccine does not appear to be entirely
effective, nor are the correlates of protection known. We performed an ELISA to ensure
seroconversion and found that NHPs 2-7 had positive titers despite one succumbing to
MARV and two others not having detectable epitopes by DPA (Figure 30).
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Figure 29 : MARV DPA results from vaccinated NHPs.
DPA of seven NHPs vaccinated with a MARV-GP VLP. NHP1 was mock treated while
NHPs 2-7 were vaccinated. Sera taken day 84 post vaccination, animals subsequently
challenged. (*) Indicates animal perished. Bars represent span of oligo recognition.
*Unpublished.
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Figure 30 : MARV ELISA for vaccinated NHPs.
DPA of seven NHPs vaccinated with a MARV-GP VLP. NHP1 was mock treated while
NHPs 2-7 were vaccinated. Sera taken day 84 post vaccination, animals subsequently
challenged. IgG antibodies were detected by ELISA using a purified recombinant
Glycoprotein of the Angola Strain of Marburg virus. Antibody levels expressed as adjusted
sum OD values while dotted line represented the threshold of the assay. MARV
seropositive >0.15. (*) Indicates animal perished. Subjects without results by DPA
checkered.
*Unpublished.
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Comparison of MARV recognition in NHP and ERB samples
We were also interested in how the response differed to GP between ERBs and
NHPs so we conducted a series of western blots. While the response appeared to be more
heterogeneous in NHPs, the response in ERBs was highly conserved between individuals
using both a commercial lysate and total virus lysate (Figure 31). We were able to identify
epitopes previously reported to be important for the MARV response in humans, although
not all (Table 12) [247]. Some of these epitopes were used to purify mAbs which were
subsequently tested for neutralization capacity and protection. While many were good
neutralizers, they did not protect guinea pigs suggesting that more than neutralization is
required [248]. Further, many mAbs target the mucin-like domain (MLD) which has been
shown to have a role in antibody-dependent enhancement (ADE) of viral infection,
dependent on cross-linking of virus-antibody complexes through FcR interaction [249].
Intriguingly we found an additional 139 oligos in ERBs to NHPs, with ERBs having more
oligos overall as well as to the major antigenic proteins (Table 13, Figure 32). The
recognition of MARV GP extends well beyond the MLD in ERBs (Figure 27).
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Figure 31 : Western blot for MARV recognition in ERBs and NHPs.
Western blot results of NHP and ERB sera reactivity to commercial GP or total virus lysate.
NHP1 was mock treated while NHPs 2-7 were vaccinated. Sera from NHPs taken day 84
post vaccination, animals subsequently challenged. (*) Indicates animal perished. ERB
2-4 were challenged with MARV twice, sera taken 56 days post first challenge. One ERB
sera sample from an unchallenged ERBs.
*Unpublished.
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Table 12 : Epitopes found in literature compared to peptides in ERB serum
EID
7673
156545
156547
181232
156548
7674
150883

Epitopes in literature
DAVTE
PTTTVPNTTNKYSTSPS
TAPENEQTSAPSKTTLL
NKYSTSPSPTPNSTAQHLVY
TNKYSTSPSPTPNSTAQHLVY
DAVTELDKN
SDDEDLATS

Epitopes pulled from IEDB [247].

Detected in ERB?
Yes
Yes
Yes
Yes
No
No
No
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Figure 32 : Comparison of clusters between ERBs and NHPs
Oligos detected by DPA for GP, NP, VP30, VP35, and VP40 of MARV for ERB (blue),
NHP (orange), and shared (gray).
*Unpublished.
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Table 13 : Oligos shared and unique between ERB and NHPs.
Protein
GP
NP
VP30
VP35
VP40
TOTAL

ERB
158
48
21
5
3
235

NHP
27
7
3
3
4
44

Shared
19
5
4
4
5
37

Oligos identified using DPA to compare recognition of MARV proteins between NHP and
ERB sera. Shared oligos are those that match 100% between species.
*Unpublished.
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Discussion
Phage display technology has been proven an effective technique to resolve total
linear epitope recognition in NHPs and Schreiber’s Bent-Winged bats to filoviruses [36,
250]. While ERBs are known to produce a robust antibody response to MARV, what
epitopes they recognize had remained elusive [87, 132]. To clarify this, we applied the
DPA technique to screen all oligos from filoviruses. We identified which regions ERBs
recognize of MARV and found fundamental differences to what is seen in primates.
While humans and primates are known to produce an antibody response to MARV,
the mechanism(s) in which they protect survivors remains unknown. However, much work
has been done to characterize panels of neutralizing antibodies from MARV survivors [79].
The antibodies primarily targeted what is thought to be the NPC1 receptor-binding domain
of MARV GP which include Q128 and N129. Other antibodies that are successful in
humans target the wing domain of MARV, which is not present in EBOV (435aa-500aa)
[79]. Intriguingly, a few mouse antibodies have been recovered that bind synthetic MARV
peptides from 401aa-420aa, 421aa-435aa, and 411aa-430aa but only antibodies to
411aa-430aa prevent viral cleavage and ultimately escape [251].
We found that ERBs recognize a larger portion of MARV GP than primates, almost
the entire region predicted to be antigenic. This recognition breadth is greater than what
is seen in primates by hundreds of base pairs in either direction and spans important
regions such as the GP1/GP2 cleavage site (435aa). This presents with two possibilities,
ERBs antibodies bind and prevent escape of the endosome by occluding the cleavage
site or antibodies bind and prevent entry of cells as the entry receptor is still not well
characterized for MARV (Figure 33). We not only identified what was antigenic, but what
regions are not antigenic as we found no recognition in any bats examined in the first and
last hundred amino acids. As the immune response is complex, likely a combination of
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antibodies affords ideal protection and reduces the chances of viral escape.
While DPA allowed us to examine recognition of all MARV proteins, we found the
most public response to be in GP with little, if any, shared epitopes identified in the other
proteins suggesting a GP-dominated response similar to what is reported for humans and
filoviruses [252]. Interestingly, in humans who are symptomatic the response is primarily
targeted against GP while in asymptomatic individuals the primary response is to VP40
[253]. Additionally, the region of GP1 recognized is larger in asymptomatic EBOV patients
than those who succumb suggesting broader recognition may afford protection and
contribute to the asymptomatic presentation [253].
Phage display is a versatile technology that allows for presentation of many
oligopeptides for screening antibodies, a prime place to start when characterizing the
recognition of the B and T cell response [254, 255]. However, while we characterized the
linear epitopes using DPA, a short coming of this approach is the inability to detect
discontinuous epitopes. The polyclonal response to a pathogen includes multiple
specificities primarily comprised of structural discontinuous epitopes [256]. Nor does DPA
detect non-contact residues which can confer important conformational changes affecting
antigen binding. Further, DPA identifies regions of recognition but does not directly identify
the functional epitope, which consists of three to five hot spot residues critical to binding
[256].
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Figure 33 : Structure of recognition site on surface of MARV GP.
The crystal structure of MARV GP (blue) bound by a human antibody (yellow) for scale,
PDB: 5MOL). ERB recognition profile (red) is surface accessible.
*Unpublished. Preparing for Viruses.
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Chapter 5:

Conclusion

Summary findings
In my dissertation I have discussed three integral components of the B cell
response in Egyptian rousette bats and how these features may contribute to the ability of
this host to withstand MARV infection, with implications for how ERBs handle viral
infections generally. In my first chapter I presented the complete IGH locus for ERBs. The
challenge with loci like these are the high repetition and diversity between species. We
painstakingly and meticulously curated sequences to bridge all previously unassembled
regions and aided by optical mapping constructed a final contiguous locus- never before
done for another bat species and rarely achieved in general due to the complexity and
ambiguity. Further, the annotation of germline genes was imperfect due to species
divergence and so each gene was manually assessed and annotated to ensure the
highest quality and confidence in RaegypIGH3.0. In the second chapter I addressed the
lack of B cell repertoire data for ERBs. I developed a protocol for IgSeq in ERBs and
analyzed the results using agnostic software to avoid species-biases. I found increased
SHM in IgM and defined this as a major mechanism of secondary diversity in ERBs,
highlighted the ~66% decrease in combinational diversity in ERBs, and identified unique
features of ERB CDR3s. In my third chapter I sought to define the antigen recognition of
ERB Igs to MARV, using a phage display technology developed for filoviruses. We found
a unique recognition of MARV glycoprotein and hypothesize the potential to control
infection by preventing endosomal escape. The references we created and tools we
developed will contribute to the growing field of bat research and aid researchers in the
field to ask more targeted questions about B cell biology and how it relates to MARV and
other infections within ERBs.
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Future Directions
Call for better characterization of ERBs as a model and review of what is known
Despite the advancements made with this dissertation, how ERBs overcome
MARV remains unknown. However, much has been learned about the ERB immune
system, V(D)J repertoire, and recognition of MARV epitopes compared to primates that
may contribute to how ERBs respond to MARV and pathogens in general. The work here
adds to the diverse knowledge already accumulated for the bat anti-viral immune response
[26, 29, 36, 85, 86, 125, 129, 133, 139, 141, 154, 223, 257-261]. We recently reported a
number of genomic differences between ERBs and humans that supported disease
tolerance [85]. However, an important factor to consider is that gene regulation,
particularly during infections, can critically alter infection outcome and therefore
expression or kinetic validation is paramount to the relevance of these genomic
differences. Moreover, absence of genes or gene families does not preclude other proteins
from compensating or replacing function. Thus while gene analysis provides context for
hypotheses, they on their own require additional studies to distinguish between tolerance
and resistance. This has been addressed with both in vitro and in vivo transcriptomic
experiments, however, both have potential pitfalls to consider. Cell culture assays have
been used to determine permissibility to viral replication and for testing of receptor
signaling pathways, however, some studies are done in immortalized cells that act
differently from primary cultures and are well known to have additional changes in cell
localization, cell recruitment, and cell to cell interactions than in a whole animal [262].
Transcriptome studies on in vivo experiments come with the enormous hurdle of having
to house and breed bat colonies and the added difficulty of determining route, dose, of
challenge to establish infection [43]. Fortunately, research on ERBs is aided establishment
of a breeding colony in containment at the Center for Disease Control and Prevention,
creation of a high-quality genome and transcriptome, and generation of ERB-specific

124
protocols and reagents.
Much work has been done to characterize the disease course in ERBs to MARV
infection. Viremia is known to peak on days 5-6 post infection, typically at lower levels than
in humans, followed by oral shedding that peaked days 7-8 post-infection, and finally
dissemination to tissues including spleen, liver, kidney, and salivary glands [42, 43, 263].
Viral replication is not associated with increased white blood cell counts, or any signs of
clinical infection like changes in weight or temperature. Further, there is a lack of evidence
for inflammatory infiltrates in infected tissues [43]. Viremia is cleared by day 13 and
shedding ends by day 19. An interesting co-housing experiment resulted in MARV
transmission to uninfected bats 4-7 months after experimental infection supporting the
potential for long latent periods without detectable viral replication [11]. Immunity is known
to be established because upon secondary challenge of previously MARV-infected ERBs
there is no detectable viral replication or shedding [132]. However, no long term study has
been done to confirm viral persistence nor are the mechanisms of persistence for
filoviruses in humans well understood.
Unlike in other pteropus bats, ERBs have been shown to have no constitutive
expression of type I IFNs [125] but that IFN is induced in cell lines with Sendai virus
suggesting that responses to one virus in ERBs is not applicable to all [85]. It also appears
that type I genes are expanded in ERBs relative to the best studied closest relative,
Pteropus alecto [85]. This recent genome revealed substantial variations in the NK cell
receptor repertoire, namely the lack of functional killer cell immunoglobulin receptors
(KIRS) and all killer lectin-like receptors (KLRs) encoding either 1) activating and inhibitory
interaction motifs, or 2) inhibitory interaction motifs only [85]. This highlights the need for
continued characterization of Chiropteran species and underscores the importance of not
simplifying findings from one species of bat to another- even within the same suborder.
This highlights the need for more standardized methods for assessing novel
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viruses and host-pathogen relationships. For example, not all MARV strains are used in
every study nor are consistent cell lines utilized making comparative analysis difficult. For
example, ERB bone marrow derived dendritic cells (BMDCs) are susceptible to MARV
infection and active viral transcription occurs up to three days post infection with MARV371
(ERB derived strain), but to lesser levels than described for MARV-Musoke (human
derived strain) in human myeloid derived dendritic cells (MDDCs) [259]. This could be due
to difference in virus isolates (bat versus human) or cell preparations (BMDCs versus
MMDCs), or perhaps due to induction of strong antiviral responses in bat DCs. Infection
of BMDCs resulted in significant upregulation of IFN-related genes with antiviral properties
and significant downregulation of genes and pathways for DC maturation and adaptive
responses [259]. One gene, CCL8 which encodes a chemokine responsible for recruiting
leukocytes to infection was downregulated in bat cells whereas it is known to be
upregulated throughout disease in NHPs. Similarly, CXCL2, a pro-inflammatory
chemokine, is upregulated in mice that succumb to EBOV but downregulated in ERB
BMDCs. These studies are important in elucidating the differences between human and
bat responses, but highlight a major flaw in transcriptomic comparisons between species.
Indeed, even between mice, NHPs and humans significant differences exist in the
transcriptome landscape [264, 265]. This is likely only exacerbated in a species such as
ERBs which are much further away in evolutionary time, requiring a more discerning
characterization of cells and base levels. Further, biologically relevant changes are still
debated in the field. A two-fold increase or decrease does not necessarily correlate to
more or less importance in outcome and in fact, fold changes of <2 can be important
biologically but are often removed from transcriptomic analysis [266].
While genomic and transcriptomic analyses are necessary starting points in novel
species characterization, much can be missed since current pipelines are inherently
biased based on what is known. In our annotation of this locus and others we found
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unannotated genes that were previously reported as missing, unannotated genes that are
more divergent from the closest relative sequenced, misannotated genes that contained
extraneous exons and more. As sequencing of new species increases, there is a need for
more meticulous annotation and validation outside of what is known for human. This is
exacerbated by the incomplete understanding of human genetics as new species are
inevitably compared to the human reference, which remains imperfect and still contains
hundreds of gaps [267-269].
Another common pitfall of comparisons is the presumption that a gene with a
known function in humans will have a similar function in a new species despite high
sequence variation. In the case of IFNs, there is remarkable variability across species in
sequence, number, regulation, and expression [270]. It was recently demonstrated that
ERB IFN gamma (IFNγ) shares limited sequence similarity to human counterparts [125].
This group hypothesized that how filoviruses antagonize the innate immune response in
bats might not mimic human. They found that type 1 IFNs induced an immune response
in human and bat cells but bat type II IFNs only stimulated rousette cells suggesting they
function differently to human IFNs. Beyond the well characterized IFNα and IFNδ
subtypes, recent works have shown significant expansions in the number of IFNω genes
of bats, pigs, and cattle which are poorly understood [271]. This underscores the need for
extensive research to characterize this model and to avoid attributing known phenomena
in the immune response in humans, mammals, or even other bats, to ERBs.
To this end, I propose the following in continuation of the findings in this
dissertation: 1) A systematic characterization of ERB Igs, FcRs and functions, 2) an indepth characterization of the V(D)J response to MARV in ERBs, and 3) validation of MARV
endosomal entrapment. These experiments would further the field significantly and better
define features of this model organism.
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Effector functions
We identified numerous differences in ERBs Igs and FcRs which demand further
investigation. As there is significant differences between even mice and humans which
are much closer evolutionarily, the FcRs and how they pair are likely unique in ERBs to
both humans and mice. An interesting next step would be to determine the combinations
in which these pair, and what cells these receptors are expressed on as well as what
mechanisms are induced. The absence of in vitro MARV neutralization activity in more
than 50 ERB sera indicates that clearance of MARV by humoral response in ERBs relies
on other antibody-mediated functions and/or innate immune response [133]. Three
mechanisms of Ig mediated immunity: antibody-dependent cellular cytotoxicity (ADCC),
antibody-dependent cellular phagocytosis (ADCP), and complement mediated lysis
(CML).
The binding specificities for each ERB FcR are not known. As FcRs play important
roles in antibody effector function, understanding FcR specificity is critical to studying
these processes. As no bat-specific reagents to explore this exist, we could create a series
of hybrid antibodies (hAb) with the Fab domain of the monoclonal anti-MARV antibody,
FILORAB3, and the Fc domain of each ERB Ig. A molecular tag would be added so we
could detect if the chimeras bind antigen, allowing us to dissect the binding ability of each
ERB FcR to each Ig by way of fluorescence similar to what has been shown in mice (Figure
34) [81]. To validate this interaction, both the FcR and the Fc would be modified to ablate
binding (Fcs will be aglycosylated and FcRs will be synthesized with mutations in residues
known to be crucial for Fc/FcR interactions in humans along the second domain of the
receptor) and subjected to the same in vitro and immunoprecipitation assays. Antibody
dilution buffer can be used as a negative control to account for background and the Fab
portion of polyclonal sera as an experimental negative control as it will lack the Fc domain
and should not bind FcRs.
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A major mode of action of many therapeutic EBOV mAbs is ADCC [272]. This
mechanism relies on the ability for FcRs on effector cells such as NK cells to recognize
and bind the Fc portion of Igs. Despite numerous attempts to purify NK cells from ERB
PBMCs, no reagents exist to select for and culture this cell population. Although there are
commercially available human and mouse NK cell lines, the genes associated with NK
cell receptors vary significantly between humans, mice and ERBs, leading us to suspect
these cells will not be ideal alternatives as they would lack the ERB FcRs. Instead, I would
transfect ERB FcRs into a mammalian NK cell line (NK-92) and test the ability of ERB sera
to induce ADCC. MARV GP can be transfected into target bat cells and then incubated
with sera from MARV infected ERBs [273] (Figure 34). ADCC can be measured by
apoptosis in wells with FcRs and Ig compared to Ig alone, NK cells alone, bat cells alone,
and Triton-x treated cells (apoptosis positive control). As a negative control of FcR
function, we can aglycosylate sera previous to addition of NK cell surrogates to ablate
ADCC activity [274].
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Figure 34 : In vitro ADCC assay.
ADCC relies on the ability for FcRs on effector cells such as NK cells to recognize and
bind the Fc portion of Igs. MARV GP will be transfected into target bat cells derived from
adult ERB kidneys (RoNi/7) and then incubated with sera from MARV infected ERBs.
Additionally this can be repeated in containment with virus (not depicted). Following
incubation, cells will be washed to remove any unbound antibodies and then incubated
with NK cells expressing FcRs, ADCC will be measured by apoptosis in wells with FcRs
and Igs.
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Our findings in Chapter 1 have indicated that ADCP is a potential function of
multiple ERB Igs. Additionally, this mechanism has been identified as an important mode
of action for filovirus mAb therapeutics [54]. Phagocytosis removes infected cells and can
be mediated by macrophages, monocytes, dendritic cells, or neutrophils. To test the
ADCP function of ERB serum we could label target cells (primary culture of monocytes)
with a pH sensitive dye that fluoresces only in mature phagosomes and quantify with cell
imaging [275]. Primary bat monocytes can then be incubated with a bat cell line
transfected with MARV GP after incubation with serum from convalescent ERBs [276].
Beads can be coated in engineered hAbs and will only be engulfed if the FcR on ERB
macrophages binds that isotypes Fc domain. As a negative control we will use
aglycosylated hAbs which would not bind FcRs but would detect GP [274]. Phagocytosis
can be measured by the amount of fluorescence detected that should only be observed if
the opsonized cell/bead is engulfed by the macrophage.
Another mechanism predicted by the work outlined in Chapter 1 for ERB Igs is
CML. For CML, apoptosis can be measured with various in vitro assays (Figure 35). We
could examine this mechanism using fluorescence dyes that do not require cell lysis and
provides a direct measurement of cytotoxicity rather than common indirect indicators such
as release of ATP or activity of lactate dehydrogenase. Antibodies that recognize viral
antigens on infected cells can initiate activation of the complement cascade by binding
complement via their Fc region to trigger cell death. To determine whether MARV
challenged ERBs generate antibodies capable of inducing CML, a bat cell line will be
transfected with MARV GP and incubated with ERB sera and horse complement (closest
related species with commercially available reagents) [129]. Cultures can be incubated
with fluorescent markers and assessed on a flow cytometer. Spontaneous lysis can be
measured in wells with complement but no antibodies, and total lysis can be determined
in cells incubated with 1% Triton X-100 [277]. These experiments can identify the amount
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CML contributes to control of MARV by ERB sera.
While complement is considered a major component of innate immunity, it links
the innate and adaptive responses through a variety of mechanisms including
enhancement of humoral immunity, regulating antibody effector mechanisms, and T cell
function modification. Mannose-binding lectin (MBL) activates the lectin complement
pathway and has been shown to bind EBOV effectively, but not MARV, resulting in strong
neutralization of EBOV and minimal neutralization of MARV [96]. We anticipate seeing
some CML as it has been shown to be an important mediator in multiple viral infections,
but as this pathway induces an inflammatory in other mammals (a response not
documented in ERBs during MARV infection,) CML may not be the primary mechanism of
protection [99].
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Transfect with MARV GP

Figure 35 : In vitro CML assay.
CML will be measured by the amount of apoptosis induced after incubation with antibodies
and complement. This method utilizes carboxyfluorosuccinimide ester (CFSE), a green
fluorescent probe which labels live cells and 7-aminoactinomycin D (7-AAD), a red
fluorescent probe which labels non-viable cells. This does not require cell lysis and
provides a direct measurement of cytotoxicity rather than common indirect indicators such
as release of ATP or activity of lactate dehydrogenase. Antibodies that recognize viral
antigens on infected cells can initiate activation of the complement cascade by binding
complement via their Fc region to trigger cell death. Assay can be performed in
containment with fully virulent virus as well (not shown).
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MARV-specific V(D)J response
Now that we have laid the groundwork to examine MARV-specific V(D)J repertoire,
the next logical step would be to create fluorescently tagged MARV proteins to pull down
specific B cell populations and interrogate their complement of B cell receptors. Recently,
researchers from Vanderbilt University have developed a high-throughput, unbiased
methodology to screen the antibody repertoire of single B cells called LIBRA-seq (Figure
36) [278]. This method uses the 10x Genomics Chromium Single Cell Immune Profiling
Solution to recover DNA-barcoded antigens and B cell receptor sequences simultaneously
to overcome the limitations of fluorescence based screening methods. To date this has
been shown to work effectively in human HIV samples and identified a diverse new panel
of antibodies [278]. This process may encounter significant challenges as purification
would need to be tested and employed in containment. However, once it is validated this
could be used for all high-consequence pathogen samples for novel antibody discovery
which would be a significant benefit to the filed.
This method combines barcoding and antigen specificity. A library of MARV
antigens would be labeled with the same flurophore to enable sorting of MARV-positive B
cells by fluorescence activated sorting (FACS). Individual B cells will be sorted using
droplet microfluidics and then BCR transcripts tagged with a common cell barcode
attached to a bead to ensure direct mapping of BCR sequence to antigen detected (Figure
36). Single-cell suspensions will be loaded onto the Chromium Controller microfluidics
device (10x Genomics) and processed under the B cell Single Cell V(D)J solution to
manufacture’s suggestions to capture 4,000 B cells per 1/8 10 cassette. Libraries will be
prepared following the CITE-seq protocol, adaptor removed by bead cleanup, and
quantified by qPCR. Samples will be sequenced on the NovaSeq 6000 at 2.5% of a flow
cell. Reads will be processed with the LIBRA-seq pipeline, which takes paired-end FASTQ
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files and annotates reads for each barcode, UMI, and antigen. V(D)J will be annotated
with our custom germline reference RaegyptBCR3.0.
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Figure 36 : Libra-seq for antigen-specific VDJ-VJ paired sequenced.

PBMCs from humans are mixed with DNA-barcoded antigens and purified based on
each antigen by flow cytometry. Single cell sequencing and functional assays can be
done on individual clones.
High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity [278].
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Validation of novel epitopes and endosome entrapment mechanism
Finally, I identified regions of MARV GP ERBs recognize that may be protective.
To test if these epitopes are protective, we could modify GP to ablate the binding site. If
the epitope was protective for ERBs then the ablation will lead to disease presentation.
However, as this is a dual-use research concern, instead I recommend purifying bat
antibodies that recognize the epitope by immunoprecipitation. Once we identify which
sequence generates the protective antibody, we can synthesize it and test it in NHPs.
Additionally, the mechanism in which ERBs are protected is unknown. Although has been
shown that ERB IgG doesn’t neutralize MARV, the location of epitopes I identified suggest
a difficulty to escape the endosome (Figure 37). I would utilize fluorescently labeled MARV
GP virus-like particles (VLPs) to monitory where these antibodies bind and control virus
[279] If it is indeed endosomal entrapment, we should be able to follow in real-time the
VLPs and the endosome would fluoresce after the cell is infected and diminish after
acidification and degradation of the particle. Further, the ablated binding mAbs we created
can be used to show the VLPs can escape the endosome and infect more cells to serve
as a positive control for mAb efficacy.
Recombinant vesicular stomatitis virus (VSV) expressing MARV glycoprotein
(rVSV-GP-MARV) will be stained with a fluorophore and incubated with a bat cell line such
as RoNi/7, fixed and examined after two hours. As the GTPase Rab7 specifically
associated with late endosomes, we will use this as a marker for the compartment and
identify co-localization of internalized virions [280]. The plasma membrane will be
incubated with different fluorophore and external viral particles detected with the mouse
monoclonal specific for MARV GP. The GP antibodies will be detected with a secondary
goat anti-mouse antibody. After washing with PBS cells will be mounted to glass slides
and fluorescence monitored on an epifluorecent microscope.
The endosomal proteases cathepsin B and cathepsin L are required for MARV to
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enter cytoplasm and infect host cells [281]. Another experiment to test the mechanism of
these antibodies would be to incubate MARV-GP with ERB antibodies, followed by
washing and incubation with cathepsins. Proteins can be visualized on a western blot to
detect successful or inhibited cleavage. The negative control would be incubated with PBS
instead of sera, and the positive control would be a monoclonal antibody built to the
GP1/GP2 cleavage interface.
Although we made significant strides toward identifying the regions of MARV ERBs
can recognize, the discrete epitopes remain uncharacterized. While western blots with
NHP serum posed minor challenges to achieve satisfactory results, ERB serum and the
few reagents that exist had unavoidable background that made quantitation out of the
question and detection difficult. Currently, the only antibody for ERB Ig was created in a
Yangochiroptera species that is reported to have some cross-reactivity but in our hands
has proven unreliable. To this end, I would next make multiple ERB Ig-specific monoclonal
antibodies in a mouse background. While this is an expensive and timely, it would push
the field forward and make ERBs easier to use as a model organism.
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Figure 37 : Endosomal entrapment illustration.
Hypothesis that if ERB antibodies bind GP1/GP2 cleavage site than viruses won’t be able
to escape endosome and will be subsequently degraded by acidification.
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Concluding hypotheses and approaches
Beneficial infection hypothesis
While infection with MARV in humans and primates results in a potentially lethal
hemorrhagic fever, ERBs are resistant to these consequences. However, it is well known
that numerous viruses present asymptomatically in humans as well. For example,
influenza virus infections are associated with a wide range of manifestation from
asymptomatic to fatal [282]. Herpes Simplex Virus-2 (HSV-2) is widespread in part
because individuals can shed without symptoms [283]. Epstein Barr virus is (EBV) results
in numerous asymptomatic cases because of an effective host immune response [284].
EBV is able to persist for a lifetime in the host in a subset of memory B cells where the
virus maintains a latent state to remain hidden from the immune system. Control of EBV
is thought to occur through the combination of CD8+ T cells, and NK cells to a lesser
extent. As EBV periodically re-emerges and can be shed, the virus persists at a population
level as well as individually. While the tropism for MARV in humans is defined, the tissues
that MARV targets preferentially in ERBs is not yet determined. Further, the prevalence of
MARV in wild adult ERBs (7-8 months of age) is consistent year round (2.4% PCR, 21.5%
seroprevalence) [11]. If the virus persists in ERBs lifelong, it is possible these sporadic
shedding events allow for maintenance within the colony to continually expose new
juveniles. In EBV and other cytomegaloviruses, transmission first occurs in early childhood
through genital excretions at birth, breast milk, or saliva from a family member [285].
Studies assessing EBV have shown that humans infected with EBV before age two had
lower risk of IgE sensitization, decreasing allergies [285]. Although this mechanism is not
well understood in humans, it offers an interesting avenue of thought for ERBs and age of
exposure to MARV. This raises the question of what benefit MARV might serve ERBs. As
it is well maintained within colonies without obvious detriments, it could potentially serve
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a beneficial purpose. Perhaps infection as juveniles helps stack the immune system for a
decrease in IgE sensitivity, allowing for the handling of more IgE overall.
One fascinating finding of this work was the expansion of IgE genes. While IgE
was the last of the five human antibody classes to be discovered and is commonly
associated today with allergic disease manifestation, its role in mammalian evolution
appears to be primarily focused on defense against parasites and venoms [286]. Indeed,
while IgE induced allergic inflammation can be deleterious, when the target is not an
autoantigen but a response to helminths/ectoparasite bites- the development of effector
mechanisms help clear parasites. Further, chronic infection turns on downregulation of
inflammation and tissue damage is in part mediated by regulatory T cells and IL10
secretion [287]. In allergic disorders these down regulatory mechanisms do not fully
develop or are lost by the overwhelmed inflammatory response [287]. As it is well known
that ERBs host numerous ectoparasites, they may have evolved to have a lessinflammatory IgE response as a result [288]. Further it has been posited for dogs that the
heightened parasite burden they endure correlates with elevated overall IgE serum levels
[289]. Based on the work presented here, I hypothesize that MARV infection in ERBs helps
prime the immune system for recurrent stimulation of the IgE response. This is based on
the principle that co-habitation with ectoparasties has led to a less-inflammatory response
with consistently stimulated IgE in bats [290].
To determine if MARV has a beneficial impact on the immune response to
parasites, and if time of exposure is relevant I would conduct an in vivo double challenge
study. I would challenge 16 juveniles and 16 adult ERBs with MARV, then challenge
groups of four with common ectoparasites for ERBs or PBS and monitor for differences in
outcome including weight, fever, blood chemistries, and antibody titers. An additional 12
ERBs I would not challenge with MARV but would challenge with ectoparasites alone. If
MARV infection plays a role in decreasing IgE sensitization response to ectoparasites, I
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would anticipate to observe symptoms to infection in the MARV-naïve animals. However,
it should be noted that ectoparasite challenge studies are not currently well defined and
would require significant troubleshooting to develop and validate.
Affinity maturation hypothesis
Another potential reason ERBs maintained two IgE genes is to aid affinity
maturation for the IgE response by allowing sequential class switching and accumulation
of SHMs. It is thought that increased SHM leads to antibodies with increased specificity,
and thus more rounds of affinity maturation leads to highly specialized antibodies. The
isolation of the first HIV-1 broadly neutralizing antibodies revealed mutation frequencies
as high as 30%, well above the 4-6% frequency typically of anti-pathogen IgG [291]. In
mice, it is known that high affinity IgE is produced through sequential class switching
(μ→γ→ε) in which the intermediary phase of IgG is necessary for the IgE response
through inherited SHM from IgG1 [292]. In contrast, low affinity is produced through direct
class switching (μ→ε) and has much less SHMs. Further, mice without IgG1 cannot
produce high affinity IgE even after multiple immunizations. To this end, ERBs may have
maintained two IgE genes to undergo sequential class switching from the IgG response
to IgE and then again to produce highly curated responses by allowing for the
accumulation of SHMs over an additional round of switching (μ→γ→ε→γ→ε). This can be
tested by examining the V(D)J repertoire of IgE+ B cells after sequential challenges with
a series of antigens. Plasma cells would be sorted and purified for antigen-specific cells
and bat-specific antibodies for IgG and IgE. I would expose groups of ten bats on day 0,
day 28, and take blood on days 1, 3, 14, 29, 30, 42, 56. IgE+ B cells would be assessed
on days: 1, 3, 29, 30 and IgG+ B cells on day 14, 28, 42, 56. Primers unique to each
isotype and subclass will be used to examine the potential for sequential class switching
and accumulation of SHMs. Alternatively, an organoid culture of ERB lymph nodes could
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be established and stimulated with common immune mediators and test the production of
antibodies over sequential additions of stimulant and analyzed in a similar way as plasma
cells above [293].
Summary
Zoonoses cause more than half of all emerging diseases and bats host more
zoonotic viruses than any other studied mammal. Increasing encroachment and exposure
of humans to new species poses the risk of spillover events with the potential to cause
severe disease such as the 2004 Marburg virus outbreak, the 2013-2016 Ebola virus
outbreak, and the ongoing SARS-CoV-2 pandemic. Understanding the immunological
mechanisms that protect reservoir hosts can offer insights into development of better
medical counter measures. Further, as bats and the ERB in particular is able to harbor
multiple human pathogenic viruses, ERBs may utilize pan-viral mechanisms of control that
would be highly beneficial to potentially combating disease X. The work here contributes
substantially to the field and revealed numerous features of ERB immunoglobulins that
support the model of disease tolerance. These immunoglobulin characteristics and overall
tolerogenic state may contribute to the asymptomatic presentation of ERBs to multiple
viruses.
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